UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of September 2024
Commission file number: 001-40231
Universe Pharmaceuticals
INC
265 Jingjiu Avenue
Jinggangshan Economic and Technological Development Zone
Ji’an, Jiangxi, China 343100
+86-0796-8403309
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F
☐
Explanatory Note
Universe Pharmaceuticals INC (the “Company”) is filing
this current report on Form 6-K to report its financial results for the six months ended March 31, 2024 and to discuss its recent corporate
developments.
Attached as exhibits to this current report on Form 6-K are:
|
(1) |
the unaudited condensed interim consolidated financial statements and related notes as Exhibit 99.1; |
|
|
|
|
(2) |
Management’s Discussion and Analysis of Financial Condition and Results of Operations as Exhibit 99.2; |
|
|
|
|
(3) |
Interactive Data File disclosure as Exhibit 101 in accordance with Rule 405 of Regulation S-T. |
This current report on Form 6-K is being incorporated by reference
into the Form F-3 of the Company (File No. 333-268028), declared effective by the U.S. Securities and Exchange Commission on
November 15, 2022.
SPECIAL NOTE REGARDING
FORWARD-LOOKING STATEMENTS
Statements in this current
report with respect to the Company’s current plans, estimates, strategies and beliefs and other statements that are not historical
facts are forward-looking statements about the future performance of the Company. Forward-looking statements include, but are not limited
to, those statements using words such as “believe,” “expect,” “plans,” “strategy,” “prospects,”
“forecast,” “estimate,” “project,” “anticipate,” “aim,” “intend,”
“seek,” “may,” “might,” “could” or “should,” and words of similar meaning
in connection with a discussion of future operations, financial performance, events or conditions. From time to time, oral or written
forward-looking statements may also be included in other materials released to the public. These statements are based on management’s
assumptions, judgments and beliefs in light of the information currently available to it. The Company cautions investors that a number
of important risks and uncertainties could cause actual results to differ materially from those discussed in the forward-looking statements,
including but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition
and pricing, government regulation, and other risks contained in reports filed by the company with the U.S. Securities and Exchange Commission.
Therefore, investors should not place undue reliance on such forward-looking statements. Actual results may differ significantly from
those set forth in the forward-looking statements.
All such forward-looking
statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements
and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation
to update any forward-looking statements to reflect events or circumstances after the date hereof.
EXHIBIT INDEX
SIGNATURES
Pursuant to the requirements of the Securities
and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
|
Universe Pharmaceuticals INC. |
|
|
Date: September 20, 2024 |
By: |
/s/ Gang Lai |
|
|
Gang Lai |
|
|
Chief Executive Officer |
Exhibit 99.1
UNIVERSE PHARMACEUTICALS INC AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
| |
As of | |
| |
March 31,
2024 | | |
September 30, 2023 | |
| |
(Unaudited) | | |
| |
ASSETS | |
| | |
| |
CURRENT ASSETS | |
| | |
| |
Cash | |
$ | 8,861,590 | | |
$ | 5,285,247 | |
Short-term investments | |
| 2,527,603 | | |
| 13,219,005 | |
Accounts receivable, net | |
| 14,384,228 | | |
| 10,667,603 | |
Due from related parties | |
| - | | |
| 61,678 | |
Inventories, net | |
| 3,386,052 | | |
| 3,343,266 | |
Advance to suppliers | |
| 368,960 | | |
| 180,643 | |
Prepayment for acquisition | |
| 3,462,460 | | |
| 3,426,535 | |
Prepaid expenses and other current assets | |
| 539,240 | | |
| 590,377 | |
TOTAL CURRENT ASSETS | |
| 33,530,133 | | |
| 36,774,354 | |
| |
| | | |
| | |
Property, plant and equipment, net | |
| 3,522,997 | | |
| 3,699,965 | |
Prepayments made to a related party for purchase of property | |
| 2,215,974 | | |
| 2,192,982 | |
Prepayments for construction in progress | |
| 9,225,725 | | |
| 9,092,996 | |
Intangible assets, net | |
| 147,652 | | |
| 148,584 | |
Investment in equity securities | |
| 692,492 | | |
| 685,307 | |
Deferred tax assets | |
| - | | |
| 656,980 | |
Prepaid expenses-related party, non-current | |
| 96,141 | | |
| 35,864 | |
TOTAL NONCURRENT ASSETS | |
| 15,900,981 | | |
| 16,512,678 | |
| |
| | | |
| | |
TOTAL ASSETS | |
$ | 49,431,114 | | |
$ | 53,287,032 | |
| |
| | | |
| | |
LIABILITIES AND SHAREHOLDERS’ EQUITY | |
| | | |
| | |
| |
| | | |
| | |
CURRENT LIABILITIES | |
| | | |
| | |
Short-term bank loans | |
$ | 4,431,949 | | |
$ | 5,482,456 | |
Accounts payable | |
| 7,763,981 | | |
| 4,585,285 | |
Taxes payable | |
| 172,374 | | |
| 434,758 | |
Due to related parties | |
| 5,515,160 | | |
| 540,096 | |
Accrued expenses and other current liabilities | |
| 2,726,078 | | |
| 2,711,736 | |
TOTAL CURRENT LIABILITIES | |
| 20,609,542 | | |
| 13,754,331 | |
| |
| | | |
| | |
Long-term bank loans | |
| 2,077,476 | | |
| - | |
TOTAL LIABILITIES | |
| 22,687,018 | | |
| 13,754,331 | |
| |
| | | |
| | |
COMMITMENTS AND CONTINGENCIES | |
| | | |
| | |
| |
| | | |
| | |
SHAREHOLDERS’ EQUITY | |
| | | |
| | |
Ordinary shares, $0.01875 par value, 166,666,666 shares authorized, 3,645,974 and 3,625,000 shares issued and outstanding as of March 31, 2024 and September 30, 2023, respectively | |
| 68,362 | | |
| 67,969 | |
Additional paid in capital | |
| 29,278,766 | | |
| 29,279,159 | |
Statutory reserve | |
| 2,439,535 | | |
| 2,439,535 | |
Retained earnings | |
| (2,942,153 | ) | |
| 10,159,304 | |
Accumulated other comprehensive loss | |
| (2,100,414 | ) | |
| (2,413,266 | ) |
TOTAL SHAREHOLDERS’ EQUITY | |
| 26,744,096 | | |
| 39,532,701 | |
| |
| | | |
| | |
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | |
$ | 49,431,114 | | |
$ | 53,287,032 | |
The accompanying
notes are an integral part of these unaudited condensed consolidated financial statements.
UNIVERSE PHARMACEUTICALS INC AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
AND COMPREHENSIVE INCOME
(UNAUDITED)
| |
For the Six Months Ended March 31, | |
| |
2024 | | |
2023 | |
| |
| | |
| |
REVENUE | |
$ | 12,884,370 | | |
$ | 18,467,186 | |
COST OF REVENUE AND RELATED TAX | |
| 9,515,039 | | |
| 12,339,044 | |
GROSS PROFIT | |
| 3,369,331 | | |
| 6,128,142 | |
| |
| | | |
| | |
OPERATING EXPENSES | |
| | | |
| | |
Selling expenses | |
| 4,054,357 | | |
| 2,330,508 | |
General and administrative expenses | |
| 968,608 | | |
| 1,380,053 | |
Research and development expenses | |
| 86,503 | | |
| 2,268,335 | |
Total operating expenses | |
| 5,109,468 | | |
| 5,978,896 | |
| |
| | | |
| | |
INCOME (LOSS) FROM OPERATIONS | |
| (1,740,137 | ) | |
| 149,246 | |
| |
| | | |
| | |
OTHER INCOME (EXPENSES) | |
| | | |
| | |
Interest expense, net | |
| (136,613 | ) | |
| (74,569 | ) |
Other income, net | |
| 152,027 | | |
| 17,323 | |
Realized (loss) gain on short-term investments | |
| (3,094,084 | ) | |
| 166,931 | |
Change in fair value of short-term investments | |
| (7,617,502 | ) | |
| - | |
Total other (loss) income, net | |
| (10,696,172 | ) | |
| 109,685 | |
| |
| | | |
| | |
(LOSS) INCOME BEFORE INCOME TAX PROVISION | |
| (12,436,309 | ) | |
| 258,931 | |
| |
| | | |
| | |
PROVISION FOR INCOME TAXES | |
| 665,148 | | |
| 974,358 | |
| |
| | | |
| | |
NET LOSS | |
| (13,101,457 | ) | |
| (715,427 | ) |
| |
| | | |
| | |
OTHER COMPREHENSIVE INCOME | |
| | | |
| | |
Foreign currency translation adjustment | |
| 312,852 | | |
| 1,399,775 | |
COMPREHENSIVE (LOSS) INCOME | |
$ | (12,788,605 | ) | |
$ | 684,348 | |
| |
| | | |
| | |
Earnings per ordinary share - basic and diluted | |
$ | (3.59 | ) | |
$ | (0.20 | ) |
Weighted average shares - basic and diluted | |
$ | 3,645,974 | | |
$ | 3,625,000 | |
The accompanying
notes are an integral part of these unaudited condensed consolidated financial statements.
UNIVERSE PHARMACEUTICALS INC AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS
OF CHANGES IN SHAREHOLDERS’ EQUITY
FOR THE SIX MONTHS
ENDED MARCH 31, 2024 AND 2023
(UNAUDITED)
| |
| | |
| | |
| | |
| | |
Accumulated | | |
| |
| |
| | |
Additional | | |
| | |
| | |
Other | | |
| |
| |
Ordinary Share | | |
Paid in | | |
Statutory | | |
Retained | | |
Comprehensive | | |
| |
| |
Shares | | |
Amount | | |
Capital | | |
Reserve | | |
Earnings | | |
Income | | |
Total | |
Balance at September 30, 2022 | |
| 3,625,000 | | |
$ | 67,969 | | |
$ | 29,279,159 | | |
$ | 2,439,535 | | |
$ | 16,322,365 | | |
$ | (1,666,705 | ) | |
$ | 46,442,323 | |
Net loss | |
| - | | |
| - | | |
| - | | |
| - | | |
| (715,427 | ) | |
| - | | |
| (715,427 | ) |
Foreign currency translation adjustment | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 1,399,775 | | |
| 1,399,775 | |
Balance at March 31, 2023 | |
| 3,625,000 | | |
$ | 67,969 | | |
$ | 29,279,159 | | |
$ | 2,439,535 | | |
$ | 15,606,938 | | |
$ | (266,930 | ) | |
$ | 47,126,671 | |
| |
| | |
| | |
| | |
| | |
| | |
| |
| |
| | |
| | |
| | |
| | |
Accumulated | | |
| |
| |
| | |
Additional | | |
| | |
| | |
Other | | |
| |
| |
Ordinary Share | | |
Paid in | | |
Statutory | | |
Retained | | |
Comprehensive | | |
| |
| |
Shares | | |
Amount | | |
Capital | | |
Reserve | | |
Earnings | | |
Income | | |
Total | |
Balance at September 30, 2023 | |
| 3,625,000 | | |
$ | 67,969 | | |
$ | 29,279,159 | | |
$ | 2,439,535 | | |
$ | 10,159,304 | | |
$ | (2,413,266 | ) | |
$ | 39,532,701 | |
Reverse share-split adjustment | |
| 20,974 | | |
| 393 | | |
| (393 | ) | |
| - | | |
| - | | |
| - | | |
| - | |
Net loss | |
| - | | |
| - | | |
| - | | |
| - | | |
| (13,101,457 | ) | |
| - | | |
| (13,101,457 | ) |
Foreign currency translation adjustment | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 312,852 | | |
| 312,852 | |
Balance at March 31, 2024 | |
| 3,645,974 | | |
$ | 68,362 | | |
$ | 29,278,766 | | |
$ | 2,439,535 | | |
$ | (2,942,153 | ) | |
$ | (2,100,414 | ) | |
$ | 26,744,096 | |
The accompanying
notes are an integral part of these unaudited condensed consolidated financial statements.
UNIVERSE PHARMACEUTICALS INC AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS
OF CASH FLOWS
(UNAUDITED)
| |
For the Six Months Ended March 31, | |
| |
2024 | | |
2023 | |
Cash flows from operating activities: | |
| | |
| |
Net loss | |
$ | (13,101,457 | ) | |
$ | (715,427 | ) |
Adjustments to reconcile net income to net cash provided by operating activities: | |
| | | |
| | |
Depreciation and amortization | |
| 248,860 | | |
| 257,781 | |
Gain from disposal of fixed assets | |
| - | | |
| (115 | ) |
Changes in allowance for doubtful accounts | |
| (265,530 | ) | |
| - | |
Changes in inventory reserve | |
| (34,303 | ) | |
| (84,956 | ) |
Deferred income tax provision | |
| 665,148 | | |
| 556,867 | |
Realized loss (gain) on short-term investments | |
| 3,094,084 | | |
| (166,931 | ) |
Change in fair value of short-term investments | |
| 7,617,502 | | |
| - | |
Changes in operating assets and liabilities: | |
| | | |
| | |
Accounts receivable | |
| (3,346,205 | ) | |
| (1,763,903 | ) |
Inventories | |
| 26,553 | | |
| (488,746 | ) |
Advance to suppliers, net | |
| (186,782 | ) | |
| (187,460 | ) |
Prepaid expenses and other current assets | |
| 57,436 | | |
| (220,969 | ) |
Prepaid expenses-related party, non-current | |
| (60,016 | ) | |
| - | |
Accounts payable | |
| 3,136,661 | | |
| 7,928,308 | |
Taxes payable | |
| (267,456 | ) | |
| 149,684 | |
Accrued expenses and other current liabilities | |
| (14,116 | ) | |
| (465,431 | ) |
Net cash (used in) provided by operating activities | |
| (2,429,621 | ) | |
| 4,798,702 | |
| |
| | | |
| | |
Cash flows from investing activities: | |
| | | |
| | |
Purchases of property and equipment | |
| (30,189 | ) | |
| (646 | ) |
Prepayments for construction in progress | |
| (37,467 | ) | |
| - | |
Purchase of short-term investments | |
| (313,541 | ) | |
| - | |
Sale of short-term investments | |
| 313,541 | | |
| - | |
Net cash used in investing activities | |
| (67,656 | ) | |
| (646 | ) |
| |
| | | |
| | |
Cash flows from financing activities: | |
| | | |
| | |
Proceeds from bank loans | |
| 2,081,483 | | |
| 1,146,776 | |
Repayment of bank loans | |
| (1,110,124 | ) | |
| (1,146,776 | ) |
Proceeds from related party borrowings | |
| 5,096,373 | | |
| 2,080,918 | |
Net cash provided by financing activities | |
| 6,067,732 | | |
| 2,080,918 | |
| |
| | | |
| | |
Effect of changes of foreign exchange rates on cash | |
| 5,888 | | |
| 364,084 | |
Net increase in cash | |
| 3,576,343 | | |
| 7,243,058 | |
Cash, beginning of period | |
| 5,285,247 | | |
| 5,711,458 | |
Cash, end of period | |
$ | 8,861,590 | | |
$ | 12,954,516 | |
| |
| | | |
| | |
Supplemental disclosure of cash flow information | |
| | | |
| | |
Cash paid for interest | |
$ | 148,860 | | |
$ | 90,044 | |
Cash paid for income tax | |
$ | 969,914 | | |
$ | 575,132 | |
The accompanying
notes are an integral part of these unaudited condensed consolidated financial statements.
UNIVERSE PHARMACEUTICALS
INC AND SUBSIDIARIES
NOTES TO UNAUDITED
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 1 — ORGANIZATION
AND BUSINESS DESCRIPTION
Universe
Pharmaceuticals INC (“Universe INC” or the “Company”) was incorporated under the laws of the Cayman Islands on
December 11, 2019 as an exempted company with limited liability.
Universe
INC owns 100% equity interest of Universe Pharmaceuticals (International) Group (“Universe HK”), an entity incorporated
on May 21, 2014 in accordance with the laws and regulations in Hong Kong.
Jiangxi
Universe Pharmaceuticals Technology Co., Ltd. (“Universe Technology”) was formed on April 8, 2019, as a wholly foreign-owned
enterprise (“WFOE”) in the People’s Republic of China (the “PRC” or “China”).
Universe
INC, Universe HK and Universe Technology are currently not engaging in any active business operations and are merely acting as holding
companies.
Jiangxi
Universe Pharmaceuticals Co., Ltd. (“Jiangxi Universe”) was incorporated on March 2, 1998 in accordance with PRC laws
and is engaged in the research and development and manufacturing of modernized traditional Chinese medicines. Jiangxi Universe owns 100%
of the equity interests of Jiangxi Universe Pharmaceuticals Commercial Trade Co., Ltd. (“Universe Trade”), which was incorporated
on March 10, 2010 for the purposes of handling the sales and distribution of the pharmaceutical products manufactured by Jiangxi Universe.
Reorganization
A reorganization
of the Company’s legal structure (the “Reorganization”) was completed on December 11, 2019. The Reorganization involved
the incorporation of Universe INC and Universe Technology, and the transfer of 100% of the equity interests of Jiangxi Universe to
Universe Technology. Consequently, Universe INC, through its subsidiary Universe HK, directly controls Universe Technology and Jiangxi
Universe, and became the ultimate holding company of all other entities mentioned above.
The Reorganization
has been accounted for as a recapitalization among entities under common control, since the same controlling shareholders controlled all
these entities before and after the Reorganization. Results of operations for the periods presented eliminate the effects of intra-entity
transactions.
On March
25, 2021, the Company closed its initial public offering (the “IPO”) of 5,000,000 ordinary shares, par value $0.003125 per
share (the “ordinary shares”) at a public offering price of $5.00 per share. On March 29, 2021, the underwriter exercised
in full its over-allotment option to purchase an additional 750,000 ordinary shares. The closing for the sale of the over-allotment
shares took place on March 31, 2021. Gross proceeds from the IPO totaled $28.75 million. Net proceeds of the IPO, including over-allotment
shares, were approximately $25.6 million. In connection with the IPO, the Company’s ordinary shares began trading on the Nasdaq
Global Market under the symbol “UPC” on March 23, 2021.
On
May 12, 2021, through the Company’s PRC subsidiary, Jiangxi Universe, the Company established an indirect wholly controlled subsidiary,
Guangzhou Universe Hanhe Medical Research Co., Ltd. (“Universe Hanhe”) in Guangzhou City, China, for the business purpose
of conducting research and development of new pharmaceutical products in order to diversify the Company’s product offerings. As
of March 31, 2024 and as of the date of this report, Universe Hanhe has no active business operations.
On July 3, 2023, the
Company held an annual general meeting of shareholders at which shareholders, among other things, resolved:
| (a) | with immediate effect, to increase the Company’s authorized share capital from US$312,500 divided into 90,000,000 ordinary shares of par value US$0.003125 each and 10,000,000 preferred shares of par value US$0.003125 each, to US$3,125,000 divided into 900,000,000 ordinary shares of par value US$0.003125 each and 100,000,000 preferred shares of par value US$0.003125 each; |
| (b) | that, conditional upon the approval of the board of directors of the Company in its sole discretion, with effect as of the date the board of directors of the Company may determine, the authorized, issued and outstanding shares of the Company be consolidated by consolidating each 10 shares of the Company, or such lesser whole share amount as the board of directors may determine in its sole discretion, such amount not to be less than 2, into 1 share of the Company, with such consolidated shares having the same rights and being subject to the same restrictions (save as to nominal value) as the then existing shares of par value US$0.003125 each in the capital of the Company (the “Share Consolidation”); and |
|
(c) |
that, upon the effectiveness of the Share Consolidation, the Company adopt amended and restated articles of association, in substantially the form set out in Annex B in the proxy statement dated 24 May 2023, in substitution for and to the exclusion of, the memorandum of association of the Company in effect immediately prior to effectiveness of the Share Consolidation. |
The board of directors
of the Company resolved to effect the Share Consolidation on July 27, 2023 with the authorized, issued and outstanding shares to be consolidated
on a six (6) for one (1) ratio, which had the effect of reducing the number of: (a) authorized ordinary shares from 900,000,000 ordinary
shares with a par value of US$0.003125 per share to 150,000,000 ordinary shares with a par value of US$0.01875 per share; (b) issued and
outstanding ordinary shares from 21,750,000 ordinary shares with a par value of US$0.003125 per share to 3,625,000 ordinary shares with
a par value of US$0.01875 per share; and (c) authorized preferred shares from 100,000,000 preferred shares with a par value of US$0.003125
per share to 16,666,666.6666 preferred shares with a par value of US$0.01875 per share. The Company’s unaudited condensed consolidated
financial statements were retrospectively restated for effect of the 6-for-1 share consolidation. Giving the effects of the share consolidation,
there were 3,645,974 ordinary shares issued and outstanding as of March 31, 2024.
Details of the subsidiaries of
the Company as of March 31, 2024 are set out below:
| | Date of | | Place of | | % of | | |
Name of Entity | | Incorporation | | Incorporation | | Ownership | | Principal Activities |
Universe INC | | December 11, 2019 | | Cayman Islands | | Parent, 100% | | Investment holding |
| | | | | | | | |
Universe HK | | May 21, 2014 | | Hong Kong | | 100% | | Investment holding |
| | | | | | | | |
Universe Technology | | April 18, 2019 | | PRC | | 100% | | WFOE, Investment holding |
| | | | | | | | |
Jiangxi Universe | | March 2, 1998 | | PRC | | 100% | | Research and development and manufacturing of modernized traditional Chinese medicines |
| | | | | | | | |
Universe Trade | | March 10, 2010 | | PRC | | 100% | | Sales of modernized traditional Chinese medicines |
| | | | | | | | |
Universe Hanhe | | May 12, 2021 | | PRC | | 100% | | Research and development of new pharmaceutical products |
The Company,
through its wholly-owned subsidiaries, is primarily engaged in the development, manufacturing and sale of traditional Chinese medicines
derivatives (“TCMD”) products targeted to the elderly to address their physical conditions in the aging process and to promote
their general well-being. In addition, the Company also sells biochemical drugs, medical instruments, traditional Chinese medicine pieces
products and dietary supplements (collectively, “third-party products”). All of these TCMD and third-party products are currently
sold to customers including pharmaceutical companies, hospitals, clinics and drugstore chains throughout China.
NOTE 2 — SUMMARY OF
SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation and Principles
of Consolidation
The accompanying unaudited condensed consolidated
financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S.
GAAP”) for interim financial information pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”).
Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited
condensed consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements and
the notes thereto for the year ended September 30, 2023 included in the Form 20-F filed on January 30, 2024. Operating results for the
six months ended March 31, 2024 are not necessarily indicative of the results that may be expected for the fiscal year ending September
30, 2024. All inter-company balances and transactions are eliminated upon consolidation.
Reclassifications
Certain amounts on the prior-years’
consolidated balance sheets and cash flows were reclassified to conform to current-year presentation, with no effect on ending stockholders’
equity.
Uses of estimates
In preparing
the unaudited condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States
of America (“US GAAP”), management makes estimates and assumptions that affect the reported amounts of assets and liabilities
and disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statements and the reported amounts
of revenues and expenses during the reporting period. These estimates are based on information as of the date of the unaudited condensed
consolidated financial statements. Significant estimates required to be made by management include, but are not limited to, the allowance
for estimated uncollectible receivables, the realizability of advance to suppliers, inventory valuations, useful lives of property and
equipment, intangible assets, the recoverability of long-lived assets, provision necessary for contingent liabilities, revenue recognition
and realization of deferred tax assets. Actual results could differ from those estimates.
Risks
and Uncertainties
The business
operations of the Company are located in the PRC. Accordingly, the Company’s business, financial condition, and results of operations
may be influenced by political, economic, and legal environments in the PRC, as well as by the general state of the PRC economy. The Company’s
results may be adversely affected by changes in the political, regulatory and social conditions in the PRC. Although the Company has not
experienced losses from these situations and believes that it is in compliance with existing laws and regulations including its organization
and structure disclosed in Note 1, this may not be indicative of future results.
The development
and commercialization of new pharmaceutical products is highly competitive, and the industry currently is characterized by rapidly changing
technologies, significant competition and a strong emphasis on intellectual property. The Company may face competition with respect to
its current and future pharmaceutical product candidates from major pharmaceutical companies in China.
The Company’s
business, financial condition and results of operations may also be negatively impacted by risks related to natural disasters, extreme
weather conditions, health epidemics and other catastrophic incidents, which could significantly disrupt the Company’s operations.
Cash
Cash includes
currency on hand and deposits held by banks that can be added or withdrawn without limitation. The Company maintains most of its bank
accounts in the PRC. Cash maintained in banks within the People’s Republic of China of less than RMB0.5 million (equivalent to
$69,249) per bank are covered by “deposit insurance regulation” promulgated by the State Council of the People’s Republic
of China.
Accounts
receivable, net
Accounts
receivables are presented net of allowance for doubtful accounts. The Company determines the adequacy of reserves for doubtful accounts
based on individual account analysis and historical collection trends. The Company establishes a provision for doubtful receivables when
there is objective evidence that the Company may not be able to collect amounts due. The allowance is based on management’s best
estimate of specific losses on individual exposures, as well as a provision on historical trends of collections. Actual amounts received
may differ from management’s estimate of credit worthiness and the economic environment. Delinquent account balances are written-off
against the allowance for doubtful accounts after management has determined that collection is not probable. The Company recovered allowance
for uncollectable balances of $265,530 and nil for the six months ended March 31, 2024 and 2023, respectively.
Inventories,
net
Inventories
are stated at net realizable value using weighted average method. Costs include the cost of raw materials, freight, direct labor and related
production overhead. Any excess of the cost over the net realizable value of each item of inventories is recognized as a provision for
diminution in the value of inventories. Net realizable value is the estimated selling price in the normal course of business less any
costs to complete and sell products. The Company evaluates inventories on a quarterly basis for its net realizable value adjustments,
and reduces the carrying value of those inventories that are obsolete or in excess of the forecasted usage to their estimated net realizable
value based on various factors including aging, expiration dates, as applicable, taking into consideration historical and expected future
product sales. The Company recovered inventory reserve of $34,303 and $84,956 for the six months ended March 31, 2024 and 2023,
respectively.
Advances
to suppliers, net
Advances
to suppliers represent prepayments made to ensure continuous high-quality supplies and favorable purchase prices of raw materials. These
advances are directly related to the purchases of raw materials used to fulfill sales orders. The Company is required from time to time
to make cash advances when placing its purchase orders. These advances are settled upon suppliers delivering raw materials to the Company
when the transfer of ownership occurs. The Company reviews its advances to suppliers on a periodic basis and makes general and specific
allowances when there is doubt as to the ability of a supplier to provide supplies to the Company or refund an advance. As of March 31,
2024 and September 30, 2023, the Company recorded no allowance for doubtful accounts, as the Company believed that all advances to suppliers
were fully realizable.
Short-term investments
The Company’s
short-term investments consist of wealth management financial products purchased from a financial institution, which can be redeemed anytime.
The financial institution invests the Company’s fund in certain financial instruments including debt and money market securities
to generate investment income. The short-term investments are deemed to be trading securities and are measured subsequently at fair value
in the statement of financial position. Realized gain and change in fair value of short-term investments are included in the unaudited
condensed consolidated statements of operations and comprehensive income over the investment period. Realized (loss) gain generated from
such short-term investments amounted to $(3,094,084) and $166,931 for the six months ended March 31, 2024 and 2023, respectively. The
Company recorded $7,617,502 and nil change in fair value of short-term investments for the six months ended March 31, 2024 and 2023, respectively
(see Note 7).
Fair value of financial
instruments
Fair value
is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market
participants at the measurement date. A three-level fair value hierarchy prioritizes the inputs used to measure fair value. The hierarchy
requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used
to measure fair value are as follows:
|
● |
Level 1 — |
inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. |
|
● |
Level 2 — |
inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, quoted market prices for identical or similar assets in markets that are not active, inputs other than quoted prices that are observable and inputs derived from or corroborated by observable market data. |
|
● |
Level 3 — |
inputs to the valuation methodology are unobservable. |
Unless otherwise
disclosed, the fair value of the Company’s financial instruments, including cash, accounts receivable, inventories, short-term investments,
advances to suppliers, prepaid expenses and other current assets, accounts payable, short-term bank loans, accrued expenses and other
current liabilities, taxes payable and due to related parties, approximate the fair value of the respective assets and liabilities as
of March 31, 2024 and September 30, 2023 based upon the short-term nature of the assets and liabilities. The Company’s investment
in equity securities is accounted for using the measurement alternative in accordance with Accounting Standards Codification (“ASC”)
321, “Investments—Equity Securities” (“ASC 321”), which also approximates its recorded value.
The following
table presents information about the Company’s assets measured at fair value on a recurring basis as of March 31, 2024 and September
30, 2023, and indicates the fair value hierarchy of the valuation techniques that the Company
utilized to determine such fair value.
| |
Fair Value Measured as of March 31, 2024 | |
| |
Level 1 | | |
Level 2 | | |
Level 3 | | |
Total | |
Assets: | |
| | |
| | |
| | |
| |
Short-term investments | |
$ | - | | |
$ | - | | |
$ | 2,527,603 | | |
$ | 2,527,603 | |
| |
Fair Value Measured as of September 30, 2023 | |
| |
Level 1 | | |
Level 2 | | |
Level 3 | | |
Total | |
Assets: | |
| | |
| | |
| | |
| |
Short-term investments | |
$ | - | | |
$ | - | | |
$ | 13,219,005 | | |
$ | 13,219,005 | |
Property and equipment
Property
and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization of property and equipment
is provided using the straight-line method over their expected useful lives, as follows:
|
|
Useful life |
Buildings |
|
20 years |
Machinery and equipment |
|
5–10 years |
Automobiles |
|
3–5 years |
Office and electric equipment |
|
3–5 years |
Expenditures
for maintenance and repairs, which do not materially extend the useful lives of the assets, are charged to expense as incurred. Expenditures
for major renewals and betterments which substantially extend the useful life of assets are capitalized. The cost and related accumulated
depreciation of assets retired or sold are removed from the respective accounts, and any gain or loss is recognized in the unaudited condensed
consolidated statements of income and other comprehensive income in other income or expenses.
The Company
reviews the carrying value of property and equipment for impairment whenever events and circumstances indicate that the carrying value
of an asset may not be recoverable from the estimated future cash flows expected to result from its use and eventual disposition. In cases
where undiscounted expected future cash flows are less than the carrying value, an impairment loss is recognized equal to an amount by
which the carrying value exceeds the fair value of assets. The factors considered by management in performing this assessment include
current operating results, trends and prospects, the manner in which the property is used, and the effects of obsolescence, demand, competition
and other economic factors. Based on this assessment, no impairment expenses for property and equipment were recorded in operating expenses
for the six months ended March 31, 2024 and 2023.
Intangible
Assets
Intangible
assets consist primarily of land use rights and software. Under the PRC law, all land in the PRC is owned by the government and cannot
be sold to an individual or company. The government grants individuals and companies the right to use parcels of land for specified periods
of time. Land use rights are stated at cost less accumulated amortization. Intangible assets are amortized using the straight-line method
with the following estimated useful lives:
| | Useful life |
Land use rights | | 50 years |
Software | | 3 years |
The Company
reviews the carrying value of land use rights for impairment whenever events and circumstances indicate that the carrying value of an
asset may not be recoverable from the estimated future cash flows expected to result from its use and eventual disposition. In cases where
undiscounted expected future cash flows are less than the carrying value, an impairment loss is recognized equal to an amount by which
the carrying value exceeds the fair value of assets. The factors considered by management in performing this assessment include current
operating results, trends and prospects, the manner in which the property is used, and the effects of obsolescence, demand, competition
and other economic factors. Based on this assessment, no impairment of land use rights was deemed necessary for the six months ended
March 31, 2024 and 2023.
Construction-in-Progress
(“CIP”)
CIP represents
property and buildings under construction and consists of construction expenditures, equipment procurement, and other direct costs attributable
to the construction. CIP is not depreciated. Upon completion and ready for intended use, CIP is reclassified to the appropriate category
within property and equipment.
Impairment
of long-lived Assets
Long-lived
assets with finite lives, primarily property and equipment and intangible assets, are reviewed for impairment whenever events or changes
in circumstances indicate that the carrying amount of an asset may not be recoverable. If the estimated undiscounted cash flows from the
use of the asset and its eventual disposition below are the asset’s carrying value, then the asset is deemed to be impaired and
written down to its fair value. The Company recorded no impairments of these assets for the six months ended March 31, 2024 and 2023.
Investments
in Equity Securities
The Company
accounts for its equity investments in accordance with ASC 321. In accordance with ASC 321, equity investment which the Company has no
significant influence (generally less than a 20% ownership interest) with readily determinable fair values are accounted for at fair
value based on quoted market prices with the changes in fair value recognized as unrealized gains or losses in earnings. Equity investments
without readily determinable fair values are accounted for either at fair value or using the measurement alternative. Under the measurement
alternative, the equity investments are measured at cost, less any impairment, if any, plus or minus changes resulting from observable
price changes in orderly transactions for the identical or a similar investment.
From March
2009 to September 2017, the Company invested approximately $0.7 million (RMB5 million) in Jiangxi Jian Rural Commercial Bank
(“JX RCB Bank”) in exchange for 5% ownership interest in the bank. The purpose of entering into these equity investment
agreements with JX RCB Bank was to earn investment income as the bank continues to grow. The Company determined that this investment in
equity securities does not have a readily determinable fair value and, accordingly, elected the measurement alternative noted above.
The Company
initially recorded the investments at historical cost and subsequently records any dividends received from the net accumulated earnings
of the investee as income. As of March 31, 2024 and September 30, 2023, the Company’s investment in JX RBC Bank amounted to $692,492 (RMB5 million)
and $685,307 (RMB5 million), respectively, and was reported as long-term investment in equity investee on the unaudited condensed
consolidated balance sheets. Investment income was nil for the six months ended March 31, 2024 and 2023.
The investments
in equity securities are evaluated for impairment when facts or circumstances indicate that the fair value of the investments is less
than their carrying value. An impairment is recognized when a decline in fair value is determined to be other-than-temporary. The Company
reviews several factors to determine whether a loss is other-than-temporary. These factors include, but are not limited to, the: (i) nature
of the investment; (ii) cause and duration of the impairment; (iii) extent to which fair value is less than cost; (iv) financial condition
and near-term prospects of the investments; and (v) ability to hold the investment for a period of time sufficient to allow for any anticipated
recovery in fair value. There was no impairment for the Company’s investments in equity securities as of March 31, 2024 and September
30, 2023.
Revenue
recognition
To determine
revenue recognition for contracts with customers, the Company performs the following five steps : (i) identify the contract(s) with the
customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, including variable consideration
to the extent that it is probable that a significant future reversal will not occur, (iv) allocate the transaction price
to the respective performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance
obligation.
The Company
recognizes revenue when it transfers its goods and services to customers in an amount that reflects the consideration to which the Company
expects to be entitled in such exchange. The Company accounts for the revenue generated from sales of its TCMD and third-party products
on a gross basis, as the Company is acting as a principal in these transactions, is subject to inventory risk, has latitude in establishing
prices, and is responsible for fulfilling the promise to provide customers the specified goods, which the Company has control of the goods
and has the ability to direct the use of goods to obtain substantially all the benefits. All of the Company’s contracts have one
single performance obligation, namely, the promise is to transfer the individual goods to customers, and there is no separately identifiable
other promise in the contracts. The Company’s revenue streams are recognized at a point in time when title and risk of loss passes
and the customer accepts the goods, which generally occurs at delivery. The Company’s products are sold with no right of return
and the Company does not provide other credits or sales incentive to customers. Revenue is reported net of all value added taxes (“VAT”).
Disaggregation of Revenues
The Company
disaggregates its revenue from contracts by product types, as the Company believes it best depicts how the nature, amount, timing and
uncertainty of the revenue and cash flows are affected by economic factors.
Cost
of Revenue
Cost of
revenue consists primarily of the costs of raw materials, freight charges, direct labor, depreciation of buildings and machinery, warehousing
and overhead associated with the manufacturing process.
Research
and Development Expenses
The Company
expenses all internal research and development costs as incurred, which primarily comprise of employee costs, internal and external costs
related to execution of studies, manufacturing costs, facility costs of the research center, and amortization and depreciation to intangible
assets and property and equipment used in the research and development activities. For the six months ended March 31, 2024 and 2023,
total research and development expenses were approximately $86,503 and $2,268,335, respectively.
Shipping
and handling costs
Shipping
and handling costs are expensed as incurred. Inbound shipping and handling cost associated with bringing the purchased raw materials and
third-party products from suppliers to the Company’s warehouse are included in cost of revenue. Outbound shipping and handling costs
associated with shipping and delivery the products to customers are included in selling expenses.
Advertising
expense
Advertising
expenses primarily relate to promotion of the Company’s brand name and products through outdoor billboards, social media such as
Weibo and WeChat, and TV advertisement. Advertising costs is expensed as incurred or deferred and then expensed the first time the advertising
takes place. Advertising expenses are included in selling expenses in the unaudited condensed consolidated statements of income and comprehensive
income. Advertising expenses amounted to $2,773,300 and $1,340,368 for the six months ended March 31, 2024 and 2023, respectively.
Segment
Reporting
The Company
uses the management approach in determining reportable operating segments. The management approach considers the internal reporting used
by the Company’s chief operating decision maker for making operating decisions about the allocation of resources of the segment
and the assessment of its performance in determining the Company’s reportable operating segments. Management has determined that
the Company has one operating segment.
Income taxes
The Company
accounts for current income taxes in accordance with the laws of the relevant tax authorities. Deferred income taxes are recognized when
temporary differences exist between the tax bases of assets and liabilities and their reported amounts in the unaudited condensed consolidated
financial statements. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in
the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities
of a change in tax rates is recognized in income in the period including the enactment date. Valuation allowances are established, when
necessary, to reduce deferred tax assets to the amount expected to be realized.
An uncertain
tax position is recognized only if it is “more likely than not” that the tax position would be sustained in a tax examination.
The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For
tax positions not meeting the “more likely than not” test, no tax benefit is recorded. Penalties and interest incurred related
to underpayment of income tax are classified as income tax expense in the period incurred. No significant penalties or interest relating
to income taxes have been incurred during the six months ended March 31, 2024 and 2023. The Company does not believe there was any uncertain
tax provision as of March 31, 2024 and September 30, 2023.
The Company’s
operating subsidiaries in China are subject to the income tax laws of the PRC. No significant income was generated outside the PRC for
the six months ended March 31, 2024 and 2023. As of March 31, 2024 and September 30, 2023, all of the tax returns of the Company’s
PRC subsidiaries remained open for statutory examination by PRC tax authorities.
Value added tax (“VAT”)
Sales revenue
represents the invoiced value of goods, net of VAT. The VAT is based on gross sales price and VAT rates range up to 13%, depending
on the type of products sold. The VAT may be offset by VAT paid by the Company on raw materials and other materials included in the cost
of producing or acquiring its finished products. The Company recorded a VAT payable or receivable net of payments in the accompanying
unaudited condensed consolidated financial statements.
Earnings per Share
The Company
computes earnings per share (“EPS”) in accordance with ASC 260, “Earnings per Share” (“ASC 260”).
ASC 260 requires companies with complex capital structures to present basic and diluted EPS. Basic EPS is measured as net income divided
by the weighted average ordinary shares outstanding for the period. Diluted presents the dilutive effect on a per share basis of potential
ordinary shares (e.g., convertible securities, options and warrants) as if they had been converted at the beginning of the periods presented,
or issuance date, if later. Potential ordinary shares that have an anti-dilutive effect (i.e., those that increase income per share or
decrease loss per share) are excluded from the calculation of diluted EPS. For the six months ended March 31, 2024 and 2023, there were
no dilutive shares.
Foreign currency translation
The functional
currency for Universe INC is the U.S. Dollar (“US$”). Universe HK uses Hong Kong dollar as its functional currency. However,
Universe INC and Universe HK currently only serve as holding companies and did not have active operations as of the date of this report.
The Company operates only in the PRC and the Company’s functional currency is the Chinese Yuan (“RMB”). The Company’s
unaudited condensed consolidated financial statements have been translated into the reporting currency US$.
Assets and
liabilities of the Company are translated at the exchange rate at each reporting period end date. Equity is translated at historical rates.
Income and expense accounts are translated at the average rate of exchange during the reporting period. The resulting translation adjustments
are reported under other comprehensive income. Gains and losses resulting from the translations of foreign currency transactions and balances
are reflected in the results of operations.
The RMB
is not freely convertible into foreign currency and all foreign exchange transactions must take place through authorized institutions.
No representation is made that the RMB amounts could have been, or could be, converted into US$ at the rates used in translation.
The following
table outlines the currency exchange rates that were used in creating the unaudited condensed consolidated financial statements in this
report:
|
|
March 31,
2024 |
|
|
March 31,
2023 |
|
|
September 30,
2023 |
|
Period-end US$: RMB exchange rate |
|
|
7.2203 |
|
|
|
6.8676 |
|
|
|
7.2960 |
|
Period-end US$: HK exchange rate |
|
|
7.8259 |
|
|
|
7.8499 |
|
|
|
7.8308 |
|
Period average US$: RMB exchange rate |
|
|
7.2064 |
|
|
|
6.9761 |
|
|
|
7.0533 |
|
Period average US$: HK exchange rate |
|
|
7.8172 |
|
|
|
7.8303 |
|
|
|
7.8310 |
|
Comprehensive
Income
Comprehensive
income consists of two components, net income and other comprehensive income. The foreign currency translation gain resulting from translation
of the financial statements expressed in RMB to US$ is reported in other comprehensive income in the unaudited condensed consolidated
statements of income and comprehensive income.
Statement
of Cash Flows
In accordance
with ASC 230, “Statement of Cash Flows”, cash flows from the Company’s operations are formulated based upon the local
currencies. As a result, amounts related to assets and liabilities reported on the statements of cash flows will not necessarily agree
with changes in the corresponding balances on the balance sheets.
Employee Defined Contribution Plan
The Company’s
subsidiaries in the PRC participate in a government-mandated multi-employer defined contribution plan pursuant to which pension, work-related
injury benefits, maternity insurance, medical insurance, unemployment benefit and housing fund are provided to eligible full-time employees.
The relevant labor regulations require the Company’s subsidiaries in the PRC to pay the local labor and social welfare authorities
monthly contributions based on the applicable benchmarks and rates stipulated by the local government. The contributions to the plan are
expensed as incurred. Employee social security and welfare benefits included as expenses in the accompanying statements of income and
comprehensive income amounted to $111,459 and $173,740 for the six months ended March 31, 2024 and 2023, respectively.
Recent Accounting Pronouncements
The Company considers the applicability and impact
of all accounting standards updates (“ASUs”). Management periodically reviews new accounting standards that are issued. Under
the Jumpstart Our Business Startups Act of 2012, as amended (the “JOBS Act”), the Company meets the definition of an emerging
growth company, or EGC, and has elected the extended transition period for complying with new or revised accounting standards, which delays
the adoption of these accounting standards until they would apply to private companies.
In December 2019, the FASB issued ASU 2019-12,
Simplifying the Accounting for Income Taxes, as part of its Simplification Initiative to reduce the cost and complexity in accounting
for income taxes. This standard removes certain exceptions related to the approach for intra period tax allocation, the methodology for
calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. It also amends
other aspects of the guidance to help simplify and promote consistent application of GAAP. The amendments in these ASUs are effective
for the Company’s fiscal years, and interim periods within those fiscal years beginning March 31, 2024. The Company does not expect
to early adopt this guidance and is in the process of evaluating the impact of adoption of this guidance on the Company’s unaudited
condensed consolidated financial statements.
In October 2021, the FASB issued ASU No. 2021-08,
“Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers”
(“ASU 2021-08”). This ASU requires entities to apply Topic 606 to recognize and measure contract assets and contract liabilities
in a business combination. The amendments improve comparability after the business combination by providing consistent recognition and
measurement guidance for revenue contracts with customers acquired in a business combination and revenue contracts with customers not
acquired in a business combination. The amendments are effective for the Company beginning after December 15, 2023, and are applied prospectively
to business combinations that occur after the effective date. The Company does not expect the adoption of ASU 2021-04 will have a material
effect on the Company’s unaudited condensed consolidated financial statements.
In November 2023, the FASB issued ASU 2023-07,
Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The amended guidance requires incremental reportable segment
disclosures, primarily about significant segment expenses. The amendments also require entities with a single reportable segment to provide
all disclosures required by these amendments, and all existing segment disclosures. The amendments will be applied retrospectively to
all prior periods presented in the financial statements and is effective for fiscal years beginning after December 15, 2023, and interim
periods in fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently in the process of evaluating
the impact this amended guidance may have on the footnotes to its unaudited condensed consolidated financial statements.
In December 2023, the FASB issued ASU 2023-09,
Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The amended guidance enhances income tax disclosures primarily related
to the effective tax rate reconciliation and income taxes paid information. This guidance requires disclosure of specific categories in
the effective tax rate reconciliation and further information on reconciling items meeting a quantitative threshold. In addition, the
amended guidance requires disaggregating income taxes paid (net of refunds received) by federal, state, and foreign taxes. It also requires
disaggregating individual jurisdictions in which income taxes paid (net of refunds received) is equal to or greater than 5 percent of
total income taxes paid (net of refunds received). The amended guidance is effective for fiscal years beginning after December 15, 2024.
The guidance can be applied either prospectively or retrospectively. The Company is currently in the process of evaluating the impact
this amended guidance may have on the footnotes to its unaudited condensed consolidated financial statements.
Other accounting standards that have been issued
by FASB that do not require adoption until a future date are not expected to have a material impact on the unaudited condensed consolidated
financial statements upon adoption. The Company does not discuss recent standards that are not anticipated to have an impact on or are
unrelated to its unaudited condensed consolidated financial condition, results of operations, cash flows or disclosures.
NOTE 3 — ACCOUNTS RECEIVABLE,
NET
Accounts
receivable consists of the following:
| |
As of | |
| |
March 31,
2024 | | |
September 30,
2023 | |
| |
(Unaudited) | | |
| |
Accounts receivable | |
$ | 14,470,157 | | |
$ | 11,014,909 | |
Less: allowance for doubtful accounts | |
| (85,929 | ) | |
| (347,306 | ) |
Accounts receivable, net | |
$ | 14,384,228 | | |
$ | 10,667,603 | |
The Company’s
accounts receivable primarily includes the balance due from customers when the Company’s pharmaceutical products are sold and delivered
to customers. As of date of this report, approximately 81.0%, or $11.7 million, of the Company’s net account receivable balance
as of March 31, 2024 has been subsequently collected, and the remaining balance is expected to be substantially collected before September
30, 2024.
Allowance
for doubtful accounts movement is as follows:
| |
As of | |
| |
March 31, 2024 | | |
September 30, 2023 | |
| |
(Unaudited) | | |
| |
Beginning balance | |
$ | 347,306 | | |
$ | 791,827 | |
Additions | |
| - | | |
| - | |
Bad debt recovery | |
| (265,530 | ) | |
| (439,327 | ) |
Foreign currency translation adjustments | |
| 4,153 | | |
| (5,194 | ) |
Ending balance | |
$ | 85,929 | | |
$ | 347,306 | |
NOTE
4 — INVENTORIES, NET
Inventory
consists of the following:
| |
As of | |
| |
March 31, 2024 | | |
September 30, 2023 | |
| |
(Unaudited) | | |
| |
Raw materials | |
$ | 551,993 | | |
$ | 635,395 | |
Finished goods | |
| 2,870,300 | | |
| 2,777,617 | |
Inventory valuation allowance | |
| (36,241 | ) | |
| (69,746 | ) |
Total inventory, net | |
$ | 3,386,052 | | |
$ | 3,343,266 | |
NOTE
5 — ADVANCE TO SUPPLIERS
Advances
to suppliers consist of the following:
|
|
As of |
|
|
|
March 31,
2024 |
|
|
September 30,
2023 |
|
|
|
(Unaudited) |
|
|
|
|
Advances to suppliers for inventory raw material purchase |
|
$ |
368,960 |
|
|
$ |
180,643 |
|
Less: allowance for doubtful accounts |
|
|
- |
|
|
|
- |
|
Advances to suppliers |
|
$ |
368,960 |
|
|
$ |
180,643 |
|
Advances
to suppliers represent prepayments made to suppliers to ensure continuous high-quality supplies and favorable purchase prices of raw materials.
NOTE 6 — PREPAYMENT
FOR ACQUISITION
On September
26, 2022, the Company entered into a letter of intent for an equity transfer with an individual, Mr. Xibo Liu, pursuant to which, Mr.
Xibo Liu transfers his 51% ownership in Yunnan Faxi Pharmaceuticals Co., Ltd. (“Yunnan Faxi”) to the Company at the price
of RMB72 million (approximately $10.0 million). Based on contract terms, the Company prepaid RMB25 million (approximately
$3.5 million) within three (3) business days upon signing the letter of intent. As of March 31, 2024, the prepayment was recorded
as prepayment for acquisition on the balance sheets. The acquisition is expected to be completed and the remaining balance is expected
to be paid by January 2025.
NOTE 7 — SHORT-TERM
INVESTMENTS
The Company’s
short-term investments consist of wealth management financial products purchased from financial institution, which can be redeemed anytime
at the Company’s discretion. The financial institution invests the Company’s fund in certain financial instruments including
debt and money market securities to generate investment income. Short-term investments consisted of the following:
| |
As of | |
| |
March 31, 2024 | | |
September 30, 2023 | |
| |
(Unaudited) | | |
| |
Beginning balance | |
$ | 13,219,005 | | |
$ | 13,148,594 | |
Purchase of short-term investments | |
| 313,541 | | |
| - | |
Sale of short-term investments | |
| (313,541 | ) | |
| - | |
Realized (loss) gain on short-term investments | |
| (3,094,084 | ) | |
| 38,530 | |
Change in fair value of short-term investments | |
| (7,617,502 | ) | |
| - | |
Foreign currency translation adjustments | |
| 20,184 | | |
| 31,881 | |
Ending balance of short-term investments | |
$ | 2,527,603 | | |
$ | 13,219,005 | |
Realized
(loss) gain generated from such short-term investments amounted to $(3,094,084) and $166,931 for the six months ended March 31, 2024 and
2023, respectively. The Company recorded $7,617,502 and nil change in fair value of short-term investments for the six months ended March
31, 2024 and 2023, respectively.
NOTE
8 — PROPERTY AND EQUIPMENT, NET
Property
and equipment, net, consists of the following:
| |
| |
As of | |
| |
Useful life | |
March 31,
2024 | | |
September 30,
2023 | |
| |
| |
(Unaudited) | | |
| |
Buildings | |
20 years | |
$ | 7,381,524 | | |
$ | 7,304,936 | |
Machinery and equipment | |
5-10 years | |
| 1,946,788 | | |
| 1,896,976 | |
Automobiles | |
3-5 years | |
| 74,476 | | |
| 73,703 | |
Office and electric equipment | |
3-5 years | |
| 480,015 | | |
| 474,830 | |
Subtotal | |
| |
| 9,882,803 | | |
| 9,750,445 | |
Less: accumulated depreciation | |
| |
| (6,359,806 | ) | |
| (6,050,480 | ) |
Property and equipment, net | |
| |
$ | 3,522,997 | | |
$ | 3,699,965 | |
Depreciation
expense was $246,365 and $255,203 for the six months ended March 31, 2024 and 2023, respectively. Income from disposal
of fixed assets amounted to nil and $115 for the six months ended March 31, 2024 and 2023, respectively.
NOTE
9 — INTANGIBLE ASSETS, NET
Intangible
assets, net consist of the following:
| | | | As of | |
| | Useful life | | March 31, 2024 | | | September 30,
2023 | |
| | | | (Unaudited) | | | | |
Land use rights | | 50 years | | $ | 249,018 | | | $ | 246,434 | |
Software | | 3 years | | | 20,904 | | | | 20,687 | |
Total | | | | | 269,922 | | | | 267,121 | |
Less: accumulated amortization | | | | | (122,270 | ) | | | (118,537 | ) |
Intangible assets, net | | | | $ | 147,652 | | | $ | 148,584 | |
Amortization
expense was $2,495 and $2,577 for the six months ended March 31, 2024 and 2023, respectively.
Estimated
future amortization expense for intangible assets is as follows:
Twelve months ending March 31, | |
Amortization expense | |
| |
| |
2025 | |
$ | 4,980 | |
2026 | |
| 4,980 | |
2027 | |
| 4,980 | |
2028 | |
| 4,980 | |
2029 | |
| 4,980 | |
Thereafter | |
| 122,752 | |
| |
$ | 147,652 | |
NOTE
10 — PREPAYMENT FOR CIP PROJECT
Construction
in process (“CIP”) represents direct costs of construction incurred for the Company’s manufacturing facilities. On June
25, 2021, the Company signed a construction sub-contract with sub-contractor Jiangxi Chenyuan Construction Project Co., Ltd. (“Chenyuan”),
pursuant to which, Chenyuan agreed to help the Company construct four manufacturing factory buildings and an office building with a total
estimated budget of RMB165 million (approximately $22.9 million). The construction work started on August 8, 2021, with an originally
estimated completion date on August 7, 2023. However, due to resurgence of the COVID-19 pandemic, which resulted in lingering logistic
disruption, material and labor shortage, and domestic travel restriction, at the beginning of 2024, the Company estimated the construction
work to be completed in December 2024. During 2024, new information was discovered about the topographical and surface structures of the
land, which required Chenyuan to redo the geological survey. As a result, the construction work is further delayed, and the construction
of the four manufacturing factory buildings and the office building is expected to be fully completed and put into use by December 2025
and December 2026, respectively. As of March 31, 2024, the Company had made a prepayment of approximately RMB69.2 million (approximately
$9.6 million) to Chenyuan for land improvement, building foundation and the construction of the manufacturing factories.
As of March
31, 2024, $395,759 (approximately RMB2.9 million) of the prepayment for the CIP project had been used for construction work, and the amount
was recorded as property and equipment in the unaudited condensed consolidated balance sheets. As of March 31, 2024, the remaining $9.2
million prepayment to Chenyuan was recorded as a prepayment for CIP project on the balance sheets.
As of March
31, 2024, future additional capital expenditure on this CIP project is estimated to be approximately RMB95.8 million (equivalent to $13.3
million), among which approximately $3.5 million is required for the next 12 months. The Company currently plans to support its ongoing
CIP project construction through cash collected from accounts receivable, and if necessary, borrowings from PRC banks in the future.
As of March
31, 2024, future minimum capital expenditures on the Company’s CIP project are estimated as follows:
Twelve months ending March 31, | |
Capital Expenditure on CIP | |
| |
| |
2025 | |
$ | 3,427,835 | |
2026 | |
| 8,697,700 | |
2027 | |
| 1,142,612 | |
Total | |
$ | 13,268,147 | |
NOTE
11 — PREPAYMENT FOR PURCHASE OF A PROPERTY
On
May 6, 2021, the Company entered into a real estate property purchase agreement with related party Jiangxi Yueshang Investment Co., Ltd.
(“Jiangxi Yueshang”), an entity in which the Company’s chief executive officer, Mr. Gang Lai, owned 5% equity interest
as of the date of that agreement. Pursuant to the property purchase agreement, Jiangxi Yueshang will sell and the Company will purchase
a certain residential apartment and commercial office space totaling 2,749.30 square meters, with a total purchase price of RMB32 million
(approximately $4.4 million). Pursuant to this agreement, the Company was required to make a prepayment in the amount of 50% of the total
purchase price, with 20% of the total purchase price payable upon the availability of a certificate of occupancy, and 30% of the total
purchase price payable upon delivery of the property.
As
of March 31, 2024, the Company had made a prepayment of RMB16 million (approximately $2.2 million) to Jiangxi Yueshang. The remaining
balance is expected to be paid by April 2025. Since the property is located in the urban downtown area of Ji’an City, the Company
plans to use the property for offices in June 2025.
NOTE
12 — SHORT-TERM BANK LOANS
Short-term bank loans consist
of the following:
| |
| |
As of | |
| |
Note | |
March 31,
2024 | | |
September 30,
2023 | |
| |
| |
(Unaudited) | | |
| |
Short-term bank loans: | |
| |
| | |
| |
Jiangxi Luling Rural Commercial Bank (“LRC Bank”) | |
(1) | |
$ | 1,384,984 | | |
$ | 2,467,105 | |
Bank of Communications Co., Ltd | |
(2) | |
| 1,246,486 | | |
| 1,233,553 | |
Zhujiang Rural Bank | |
(3) | |
| 415,495 | | |
| 411,184 | |
Beijing Bank | |
(4) | |
| 1,384,984 | | |
| 1,370,614 | |
Total short-term loans | |
| |
$ | 4,431,949 | | |
$ | 5,482,456 | |
NOTE
13 — LONG-TERM BANK LOANS
Long-term bank loans consist
of the following:
| |
| |
As of | |
| |
Note | |
March 31, 2024 | | |
September 30, 2023 | |
| |
| |
(Unaudited) | | |
| |
Long-term bank loans: | |
| |
| | | |
| | |
LRC Bank | |
(1) | |
$ | 2,077,476 | | |
$ | - | |
For the above-mentioned loans,
the Company recorded a total interest expense of $148,860 and $90,044 for the six months ended March 31, 2024 and 2023, respectively.
NOTE
14 — RELATED PARTY TRANSACTIONS
(a) Nature of relationships with related parties
Name | | Relationship with the Company |
Mr. Gang Lai | | Chief Executive Officer and chairman of the Company’s Board of Directors |
Mr. Yajun Hu | | General Manager of Jiangxi Universe |
Guangzhou Ningjing Investment Co., Ltd (Guangzhou Ningjing) | | Under common control of Mr. Gang Lai |
(b) Due from related parties
| |
As of | |
Name | |
March 31,
2024 | | |
September 30,
2023 | |
| |
(Unaudited) | | |
| |
Mr. Yajun Hu | |
$ | - | | |
$ | 61,678 | |
Total due from related parties | |
$ | - | | |
$ | 61,678 | |
As of September 30, 2023, the balance due from
related parties consisted of advanced funds to the Company’s director and general manager, Mr. Yajun Hu. These advances are non-interest
bearing and fully repaid on October 12, 2023.
(c) Due to related parties
| |
As of | |
Name | |
March 31,
2024 | | |
September 30,
2023 | |
| |
(Unaudited) | | |
| |
Mr. Gang Lai | |
$ | 5,515,160 | | |
$ | 540,096 | |
Total due to related parties | |
$ | 5,515,160 | | |
$ | 540,096 | |
As of March
31, 2024, the balance due to related parties mainly consisted of advances from Mr. Gang Lai, the Company’s chief executive officer
and the chairman of the board of directors for working capital purposes during the Company’s normal course of business. These advances
are non-interest bearing and due on demand.
(d) Loan guarantee provided
by related parties
In connection
with the Company’s bank borrowings from PRC Banks, certain related parties of the Company, including Mr. Gang Lai, the Company’s
chairman of the board of directors and chief executive officer, signed guarantee agreements with these banks to provide credit guarantee
for the Company’s certain loans (see Note 12 and 13).
(e) Prepayment to related
party for property purchase
As disclosed
in Note 11, on May 6, 2021, the Company entered into a real estate property purchase agreement with a related party, Jiangxi Yueshang,
to purchase certain residential apartment and commercial office space totaling 2,749.30 square meters with total purchase price of RMB32
million (approximately $4.4 million). As of March 31, 2024, the Company had made a prepayment of RMB16 million ($2.2 million)
to Jiangxi Yueshang. The remaining balance is expected to be paid by April 2025.
On January
13, 2022, Mr. Gang Lai transferred the 5% equity interest he owned in Jiangxi Yueshang to a third party. As such, after this date,
Jiangxi Yueshang is no longer the Company’s related party.
(f) Prepaid
expenses-related party, non-current
As of March
31, 2024 and September 30, 2023, the Company prepaid Guangzhou Ningjing $96,141 and $35,864 for right to use trademarks, respectively.
NOTE
15 — CONCENTRATIONS
A majority
of the Company’s revenue and expense transactions are denominated in RMB and a significant portion of the Company’s and its
subsidiaries’ assets and liabilities are denominated in RMB. RMB is not freely convertible into foreign currencies. In the PRC,
certain foreign exchange transactions are required by law to be transacted only by authorized financial institutions at exchange rates
set by the People’s Bank of China (“PBOC”). Remittances in currencies other than RMB by the Company in China must be
processed through the PBOC or other China foreign exchange regulatory bodies which require certain supporting documentation in order to
affect the remittance.
As of March 31, 2024 and September
30, 2023, $8,771,774 and $5,223,573 of the Company’s cash, respectively, was on deposit at financial institutions in the
PRC. For the six months ended March 31, 2024 and 2023, the Company’s substantial assets were located in the PRC and the Company’s
substantial revenues were derived from its subsidiaries located in the PRC.
For the
six months ended March 31, 2024, no single customer accounted for more than 10% of the Company’s total revenue. For the six months
ended March 31, 2023, one customer accounted for 14.1% of the Company’s total revenue. The Company’s top 10 customers aggregately
accounted for 23.0% and 32.9% of the total revenue for the six months ended March 31, 2024 and 2023, respectively.
Sales of
one of the Company’s major products, Guben Yanling Pill, accounted for 33.5% and 30.4% of the Company’s total revenue
for the six months ended March 31, 2024 and 2023, respectively.
As of March
31, 2024 and September 30, 2023, no customer accounted for more than 10% of the total accounts receivable balance.
For the
six months ended March 31, 2024, two suppliers accounted for 29.9% and 10.0% of the total purchases, respectively. For the six months
ended March 31, 2023, one supplier accounted for 16.2% of the total purchases.
NOTE 16 — SHAREHOLDERS’
EQUITY
Ordinary Shares
Universe
INC was incorporated under the laws of the Cayman Islands on December 11, 2019. The original authorized number of ordinary shares upon
incorporation was 50,000 shares with par value of US$1.00 per share and 50,000 shares were issued. On August
7, 2020, the Company amended its Memorandum of Association to increase the authorized number of shares to 100,000,000 shares
with par value of $0.003125 per share, and subdivide the original issued shares from 50,000 shares at par value of $1.00 per
share to 16,000,000 ordinary shares with par value of $0.003125 per share. As a result of this forward split of the
outstanding ordinary shares at a ratio of 320-for-1 share, a total of 16,000,000 shares were issued and outstanding after the split. The
issuance of these 16,000,000 shares is considered as a part of the Reorganization of the Company, which was retroactively applied
as if the transaction occurred at the beginning of the period presented.
Increased authorized share
capital and share consolidation
On July 3, 2023, the
Company held an annual general meeting of shareholders at which shareholders, among other things, resolved:
| (a) | with
immediate effect, to increase the Company’s authorized share capital from US$312,500 divided into 90,000,000 ordinary shares of
par value US$0.003125 each and 10,000,000 preferred shares of par value US$0.003125 each, to US$3,125,000 divided into 900,000,000 ordinary
shares of par value US$0.003125 each and 100,000,000 preferred shares of par value US$0.003125 each; |
| (b) | that,
conditional upon the approval of the board of directors of the Company in its sole discretion, with effect as of the date the board of
directors of the Company may determine, the authorized, issued and outstanding shares of the Company be consolidated by consolidating
each 10 shares of the Company, or such lesser whole share amount as the board of directors may determine in its sole discretion, such
amount not to be less than 2, into 1 share of the Company, with such consolidated shares having the same rights and being subject to
the same restrictions (save as to nominal value) as the then existing shares of par value US$0.003125 each in the capital of the Company
(the “Share Consolidation”); and |
| (c) | that,
upon the effectiveness of the Share Consolidation, the Company adopt amended and restated articles of association, in substantially the
form set out in Annex B in the proxy statement dated 24 May 2023, in substitution for and to the exclusion of, the memorandum of association
of the Company in effect immediately prior to effectiveness of the Share Consolidation. |
The board
of directors of the Company resolved to effect the Share Consolidation at 5:00 p.m. (Cayman Islands time) on July 27, 2023 with the authorized,
issued and outstanding shares to be consolidated on a six (6) for one (1) ratio, which had the effect of reducing the number of: (a) authorized
ordinary shares from 900,000,000 ordinary shares with a par value of US$0.003125 per share to 150,000,000 ordinary shares with a par value
of US$0.01875 per share; (b) issued and outstanding ordinary shares from 21,750,000 ordinary shares with a par value of US$0.003125 per
share to 3,625,000 ordinary shares with a par value of US$0.01875 per share; and (c) authorized preferred shares from 100,000,000 preferred
shares with a par value of US$0.003125 per share to 16,666,666.6666 preferred shares with a par value of US$0.01875 per share. The Company’s
unaudited condensed consolidated financial statements were retrospectively restated for effect of the 6-for-1 Shares Consolidation (see
Note 1). Giving the effects of the Share Consolidation, there were 3,645,974 ordinary shares issued and outstanding as of March 31, 2024.
As of March
31, 2024 and September 30, 2023, the Company had a total of 3,645,974 and 3,625,000 ordinary shares issued and outstanding,
respectively.
Underwriter warrants
In connection
with the Company’s IPO, the Company also agreed to issue warrants to the underwriter, for a nominal consideration of $0.001 per
warrant, to purchase 300,000 ordinary shares of the Company (equal to 6% of the total number of ordinary shares sold in
the IPO, not including any ordinary shares sold in the over-allotment option) (the “Underwriter Warrants”). The Underwriter
Warrants have a term of five years, with an exercise price of $5.50 per share (equal to 110% of the Company’s IPO offering
price of $5.00 per share). The Underwriter Warrants may be purchased in cash or via cashless exercise, are exercisable for five (5)
years, and will terminate on the fifth anniversary of the closing of the IPO. Management determined that the Underwriter Warrants meet
the requirements for equity classification under ASC 815-40 because they are indexed to its own stock. As of March 31, 2024, the Underwriter
Warrants were issued and outstanding, but none of them had been exercised. For the six months ended March 31, 2024 and 2023, the Underwriter
Warrants were antidilutive and accordingly were not included in the diluted EPS calculation based on treasury stock method.
Statutory reserve and restricted
net assets
The Company’s
PRC subsidiaries are restricted in their ability to transfer a portion of their net assets to the Company. The payment of dividends by
entities organized in China is subject to limitations, procedures and formalities. Regulations in the PRC currently permit payment of
dividends only out of accumulated profits as determined in accordance with accounting standards and regulations in China.
The Company
is required to make appropriations to certain reserve funds, comprising the statutory surplus reserve and the discretionary surplus reserve,
based on after-tax net income determined in accordance with generally accepted accounting principles of the PRC (“PRC GAAP”).
Appropriations to the statutory surplus reserve are required to be at least 10% of the after-tax net income determined in accordance
with PRC GAAP until the reserve is equal to 50% of the entity’s registered capital. Appropriations to the discretionary surplus
reserve are made at the discretion of the board of directors. The statutory reserve may be applied against prior year losses, if any,
and may be used for general business expansion and production or increase in registered capital, but are not distributable as cash dividends.
Relevant
PRC laws and regulations restrict the Company’s PRC subsidiaries from transferring a portion of their net assets, equivalent to
their statutory reserves and their share capital, to the Company in the form of loans, advances or cash dividends. Only PRC entities’
accumulated profits may be distributed as dividends to the Company without the consent of a third party. As of March 31, 2024 and September
30, 2023, the restricted amounts as determined pursuant to PRC statutory laws totaled $2,439,535, and total restricted net assets amounted
to $31,786,663.
NOTE 17 — COMMITMENTS
AND CONTINGENCIES
From time
to time, the Company is a party to various legal actions arising in the ordinary course of business. The Company accrues costs associated
with these matters when they become probable and the amount can be reasonably estimated. Legal costs incurred in connection with loss
contingencies are expensed as incurred. For the six months ended March 31, 2024 and 2023, the Company did not have any material legal
claims or litigation that, individually or in aggregate, could have a material adverse impact on the Company’s consolidated financial
position, results of operations and cash flows.
The Company
has an ongoing CIP project associated with the construction of a new manufacturing facility. As of March 31, 2024, future minimum capital
expenditures on the Company’s CIP project amounted to approximately $13.3 million, among which, approximately $3.4 million
is required for the next 12 months from the date of this report (see Note 10).
On May 6,
2021, the Company entered into a real estate property purchase agreement with Jiangxi Yueshang, an entity in which the Company’s
chief executive officer, Mr. Gang Lai, owned 5% of its equity interests as of the date of that agreement. Pursuant to this purchase agreement,
Jiangxi Yueshang will sell and the Company will purchase certain residential apartments and commercial office space totaling 2,749.30
square meters, with a total purchase price of RMB32 million (approximately $4.4 million). As of March 31, 2024, the Company had made a
prepayment of RMB16 million (approximately $2.2 million) to Jiangxi Yueshang. The remaining balance is expected to be paid by April 2025
(see Note 11).
NOTE 18 — SUBSEQUENT
EVENTS
On April 23, 2024, a
subsidiary of the Company, Jiangxi Universe, entered into a loan agreement with Zhujiang Rural Bank to borrow RMB3 million (equivalent
to $415,495) as working capital for two years, with the maturity date on April 20, 2026. The fixed interest rate of the loan was 3.65%
per annum. The Company pledged certain trademarks owned by the Company as collateral to guarantee this loan.
On April 26, 2024, a
subsidiary of the Company, Jiangxi Universe, signed a loan agreement with LRC Bank to borrow RMB10 million (equivalent to $1,384,984)
as working capital for one year, with the maturity date on April 25, 2025. The fixed interest rate of the loan was 4.31% per annum. Mr.
Gang Lai and Universe Trade jointly signed guarantee agreements with LRC Bank to provide credit guarantee for this loan.
On June 16, 2024, the
Company’s subsidiary, Jiangxi Universe, signed a loan agreement with Bank of Communications to borrow RMB8.1 million (equivalent
to $1,121,837) as working capital for eleven months, with the maturity date on May 13, 2025. The fixed interest rate of the loan was 3.9%
per annum. Mr. Gang Lai, Universe Trade, and an unrelated third party, Jiangxi Province Financing Guarantee Group Co., Ltd., jointly signed
guarantee agreements with Bank of Communications to provide credit guarantee for this loan.
On July 3, 2024, a subsidiary
of the Company, Jiangxi Universe, entered into a loan agreement with Beijing Bank to borrow RMB 10 million (equivalent to $1,384,984)
as working capital for one year, with the maturity date on July 3, 2025. The fixed interest rate of the loan was 4.15% per annum. Mr.
Gang Lai provided credit guarantee for this loan.
On July 15, 2024, the
Company closed its self-underwritten public offering (“Offering”) of 20,000,000 ordinary shares, par value $0.01875 per share
(the “Ordinary Shares”). The Ordinary Shares were priced at $1.25 per share. The Company raised a total of $25 million through
that Offering, before deducting Offering-related expenses of $199,830.
The Company has assessed
all subsequent events through the date that these unaudited condensed consolidated financial statements are issued and there are no further
material subsequent events that require disclosure in these unaudited condensed consolidated financial statements.
NOTE
19 — CONDENSED FINANCIAL INFORMATION OF THE PARENT COMPANY
Pursuant
to the requirements of Rule 12-04(a), 5-04(c) and 4-08(e)(3) of Regulation S-X, the condensed financial information of the parent company
shall be filed when the restricted net assets of consolidated subsidiaries exceed 25 percent of consolidated net assets as of the end
of the most recently completed fiscal year. The Company performed a test on the restricted net assets of consolidated subsidiaries in
accordance with such requirement and concluded that it was applicable to the Company as the restricted net assets of the Company’s
subsidiaries exceeded 25% of the consolidated net assets of the Company. Therefore, the condensed financial statements for the parent
company are included herein.
For purposes
of the above test, restricted net assets of consolidated subsidiaries shall mean that amount of the Company’s proportionate share
of net assets of consolidated subsidiaries (after intercompany eliminations) which as of the end of the most recent fiscal year may not
be transferred to the parent company by subsidiaries in the form of loans, advances or cash dividends without the consent of a third party.
The condensed
financial information of the parent company has been prepared using the same accounting policies as set out in the Company’s unaudited
condensed consolidated financial statements except that the parent company used the equity method to account for investment in its subsidiaries.
Such investment is presented on the condensed balance sheets as “Investment in subsidiaries” and the respective profit or
loss as “Equity in earnings of subsidiaries” on the condensed statements of income.
The footnote
disclosures contain supplemental information relating to the operations of the Company and, as such, these statements should be read in
conjunction with the notes to the unaudited condensed consolidated financial statements of the Company. Certain information and footnote
disclosures normally included in financial statements prepared in accordance with U.S GAAP have been condensed or omitted.
As of March
31, 2024 and September 30, 2023, there were no material contingencies, significant provisions for long-term obligations, or guarantees
of the Company, except for those which have been separately disclosed in the unaudited condensed consolidated financial statements, if
any.
UNIVERSE PHARMACEUTICALS
INC AND SUBSIDIARIES
PARENT COMPANY BALANCE
SHEETS
| |
As of | |
| |
March 31,
2024 | | |
September 30,
2023 | |
| |
(Unaudited) | | |
| |
ASSETS | |
| | |
| |
Cash | |
$ | 69,114 | | |
$ | 9,248 | |
Short-term investments | |
| 2,527,603 | | |
| 13,219,005 | |
Due from subsidiaries | |
| 10,785,261 | | |
| 10,878,344 | |
Total current assets | |
| 13,381,978 | | |
| 24,106,597 | |
| |
| | | |
| | |
Non-current assets | |
| | | |
| | |
Investment in subsidiaries | |
$ | 13,554,925 | | |
$ | 15,426,104 | |
| |
| | | |
| | |
Total assets | |
$ | 26,936,903 | | |
$ | 39,532,701 | |
| |
| | | |
| | |
LIABILITIES AND SHAREHOLDERS’ EQUITY | |
| | | |
| | |
| |
| | | |
| | |
CURRENT LIABILITIES | |
| | | |
| | |
Due to related parties | |
| 192,807 | | |
| - | |
TOTAL CURRENT LIABILITIES | |
$ | 192,807 | | |
$ | - | |
| |
| | | |
| | |
COMMITMENTS AND CONTINGENCIES | |
| | | |
| | |
| |
| | | |
| | |
SHAREHOLDERS’ EQUITY | |
| | | |
| | |
Ordinary shares, $0.01875 par value, 166,666,666 shares authorized, 3,645,974 and 3,625,000 shares issued and outstanding as of March 31, 2024 and September 30, 2023, respectively | |
| 68,362 | | |
| 67,969 | |
Additional paid-in capital | |
| 29,278,766 | | |
| 29,279,159 | |
Retained earnings | |
| (502,618 | ) | |
| 12,598,839 | |
Accumulated other comprehensive loss | |
| (2,100,414 | ) | |
| (2,413,266 | ) |
Total shareholders’ equity | |
| 26,744,096 | | |
| 39,532,701 | |
| |
| | | |
| | |
Total liabilities and shareholders’ equity | |
$ | 26,936,903 | | |
$ | 39,532,701 | |
UNIVERSE PHARMACEUTICALS
INC AND SUBSIDIARIES
PARENT COMPANY STATEMENTS
OF INCOME AND COMPREHENSIVE INCOME
(UNAUDITED)
| |
For the six months ended March 31, | |
| |
2024 | | |
2023 | |
Operating costs and expenses: | |
| | |
| |
General and administrative expenses | |
$ | (232,809 | ) | |
$ | (116,431 | ) |
| |
| | | |
| | |
Other income (expenses): | |
| | | |
| | |
Realized (loss) gain on short-term investments | |
| (3,094,084 | ) | |
| 166,931 | |
Change in fair value of short-term investments | |
| (7,617,502 | ) | |
| | |
Other expenses | |
| (291 | ) | |
| (507 | ) |
| |
| | | |
| | |
Equity in loss of subsidiaries | |
| (2,156,771 | ) | |
| (765,420 | ) |
| |
| | | |
| | |
Net loss | |
| (13,101,457 | ) | |
| (715,427 | ) |
Foreign currency translation adjustments | |
| 312,852 | | |
| 1,399,775 | |
Comprehensive (loss) income attributable to the Company | |
$ | (12,788,605 | ) | |
$ | 684,348 | |
UNIVERSE PHARMACEUTICALS
INC AND SUBSIDIARIES
PARENT COMPANY STATEMENTS
OF CASH FLOWS
(UNAUDITED)
| |
For the six months ended March 31, | |
| |
2024 | | |
2023 | |
CASH FLOWS FROM OPERATING ACTIVITIES: | |
| | |
| |
Net income | |
$ | (13,101,457 | ) | |
$ | (715,427 | ) |
Adjustments to reconcile net cash flows from operating activities: | |
| | | |
| | |
Equity in earnings of subsidiary | |
| 2,156,771 | | |
| 765,420 | |
Realized (loss) gain on short-term investments | |
| 3,094,084 | | |
| (166,931 | ) |
Change in fair value of short-term investments | |
| 7,617,502 | | |
| - | |
Changes in operating assets and liabilities: | |
| | | |
| | |
Due from subsidiaries | |
| 93,083 | | |
| 105,058 | |
Due to related parties | |
| 192,807 | | |
| - | |
Net cash provided by (used in) operating activities | |
| 52,790 | | |
| (11,880 | ) |
| |
| | | |
| | |
CASH FLOWS FROM INVESTING ACTIVITIES: | |
| | | |
| | |
Purchase of short-term investments | |
| (313,541 | ) | |
| - | |
Sale of short-term investments | |
| 313,541 | | |
| - | |
Net cash provided by investing activities | |
| - | | |
| - | |
| |
| | | |
| | |
EFFECT OF CHANGES OF FOREIGN EXCHANGE RATES ON CASH | |
| 7,076 | | |
| 120 | |
| |
| | | |
| | |
CHANGES IN CASH | |
| 59,866 | | |
| (11,760 | ) |
| |
| | | |
| | |
CASH, beginning of period | |
| 9,248 | | |
| 28,917 | |
| |
| | | |
| | |
CASH, end of period | |
$ | 69,114 | | |
$ | 17,157 | |
F-27
0.20
3.59
3625000
3645974
false
--09-30
Q2
2024-03-31
0001809616
0001809616
2023-10-01
2024-03-31
0001809616
2024-03-31
0001809616
2023-09-30
0001809616
us-gaap:RelatedPartyMember
2024-03-31
0001809616
us-gaap:RelatedPartyMember
2023-09-30
0001809616
2022-10-01
2023-03-31
0001809616
us-gaap:CommonStockMember
2022-09-30
0001809616
us-gaap:AdditionalPaidInCapitalMember
2022-09-30
0001809616
upc:StatutoryReservesMember
2022-09-30
0001809616
us-gaap:RetainedEarningsMember
2022-09-30
0001809616
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2022-09-30
0001809616
2022-09-30
0001809616
us-gaap:CommonStockMember
2022-10-01
2023-03-31
0001809616
us-gaap:AdditionalPaidInCapitalMember
2022-10-01
2023-03-31
0001809616
upc:StatutoryReservesMember
2022-10-01
2023-03-31
0001809616
us-gaap:RetainedEarningsMember
2022-10-01
2023-03-31
0001809616
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2022-10-01
2023-03-31
0001809616
us-gaap:CommonStockMember
2023-03-31
0001809616
us-gaap:AdditionalPaidInCapitalMember
2023-03-31
0001809616
upc:StatutoryReservesMember
2023-03-31
0001809616
us-gaap:RetainedEarningsMember
2023-03-31
0001809616
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2023-03-31
0001809616
2023-03-31
0001809616
us-gaap:CommonStockMember
2023-09-30
0001809616
us-gaap:AdditionalPaidInCapitalMember
2023-09-30
0001809616
upc:StatutoryReservesMember
2023-09-30
0001809616
us-gaap:RetainedEarningsMember
2023-09-30
0001809616
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2023-09-30
0001809616
us-gaap:CommonStockMember
2023-10-01
2024-03-31
0001809616
us-gaap:AdditionalPaidInCapitalMember
2023-10-01
2024-03-31
0001809616
upc:StatutoryReservesMember
2023-10-01
2024-03-31
0001809616
us-gaap:RetainedEarningsMember
2023-10-01
2024-03-31
0001809616
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2023-10-01
2024-03-31
0001809616
us-gaap:CommonStockMember
2024-03-31
0001809616
us-gaap:AdditionalPaidInCapitalMember
2024-03-31
0001809616
upc:StatutoryReservesMember
2024-03-31
0001809616
us-gaap:RetainedEarningsMember
2024-03-31
0001809616
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2024-03-31
0001809616
upc:UniverseIncMember
2023-10-01
2024-03-31
0001809616
upc:UniverseIncMember
2024-03-31
0001809616
upc:UniverseHKMember
2023-10-01
2024-03-31
0001809616
upc:JiangxiUniverseMember
2023-10-01
2024-03-31
0001809616
upc:UniverseTradeMember
2024-03-31
0001809616
upc:JiangxiMember
2024-03-31
0001809616
us-gaap:CommonStockMember
us-gaap:IPOMember
2021-03-25
2021-03-25
0001809616
us-gaap:IPOMember
2021-03-25
0001809616
us-gaap:OverAllotmentOptionMember
2021-03-29
0001809616
us-gaap:IPOMember
2021-03-29
2021-03-29
0001809616
us-gaap:OverAllotmentOptionMember
2021-03-29
2021-03-29
0001809616
srt:MinimumMember
2023-07-03
0001809616
us-gaap:CommonStockMember
2023-07-03
0001809616
srt:MinimumMember
us-gaap:CommonStockMember
2023-07-03
0001809616
us-gaap:PreferredStockMember
2023-07-03
0001809616
2023-07-03
0001809616
srt:BoardOfDirectorsChairmanMember
us-gaap:CommonStockMember
2023-07-03
0001809616
srt:MaximumMember
2023-07-03
0001809616
us-gaap:CommonStockMember
2023-07-27
0001809616
srt:MaximumMember
us-gaap:CommonStockMember
2023-07-27
0001809616
srt:MinimumMember
us-gaap:CommonStockMember
2023-07-27
0001809616
upc:CommonStockOneMember
2023-07-27
0001809616
upc:CommonStockTwoMember
2023-07-27
0001809616
srt:MaximumMember
2023-07-27
0001809616
us-gaap:PreferredStockMember
2023-07-27
0001809616
2023-07-27
0001809616
upc:OrdinarySharesMember
2024-03-31
0001809616
upc:UniverseINCMember
2023-10-01
2024-03-31
0001809616
upc:UniverseINCMember
2024-03-31
0001809616
upc:UniverseHKMember
2024-03-31
0001809616
upc:UniverseTechnologyMember
2023-10-01
2024-03-31
0001809616
upc:UniverseTechnologyMember
2024-03-31
0001809616
upc:JiangxiUniverseMember
2024-03-31
0001809616
upc:UniverseTradeMember
2023-10-01
2024-03-31
0001809616
upc:UniverseHanheMember
2023-10-01
2024-03-31
0001809616
upc:UniverseHanheMember
2024-03-31
0001809616
upc:UniversePharmaceuticalsIncMember
2024-03-31
0001809616
upc:JxRcbBankMember
2009-03-01
2017-09-30
0001809616
upc:JxRcbBankMember
2017-09-30
0001809616
upc:JxRcbBankMember
2023-10-01
2024-03-31
0001809616
upc:JxRcbBankMember
2023-09-30
2023-09-30
0001809616
us-gaap:FairValueInputsLevel1Member
2024-03-31
0001809616
us-gaap:FairValueInputsLevel2Member
2024-03-31
0001809616
us-gaap:FairValueInputsLevel3Member
2024-03-31
0001809616
us-gaap:FairValueInputsLevel1Member
2023-09-30
0001809616
us-gaap:FairValueInputsLevel2Member
2023-09-30
0001809616
us-gaap:FairValueInputsLevel3Member
2023-09-30
0001809616
us-gaap:BuildingMember
2024-03-31
0001809616
srt:MinimumMember
us-gaap:MachineryAndEquipmentMember
2024-03-31
0001809616
srt:MaximumMember
us-gaap:MachineryAndEquipmentMember
2024-03-31
0001809616
srt:MinimumMember
us-gaap:AutomobilesMember
2024-03-31
0001809616
srt:MaximumMember
us-gaap:AutomobilesMember
2024-03-31
0001809616
srt:MinimumMember
upc:OfficeAndElectricEquipmentMember
2024-03-31
0001809616
srt:MaximumMember
upc:OfficeAndElectricEquipmentMember
2024-03-31
0001809616
us-gaap:UseRightsMember
2024-03-31
0001809616
us-gaap:ComputerSoftwareIntangibleAssetMember
2024-03-31
0001809616
currency:CNY
2024-03-31
0001809616
currency:CNY
2023-03-31
0001809616
currency:CNY
2023-09-30
0001809616
currency:HKD
2024-03-31
0001809616
currency:HKD
2023-03-31
0001809616
currency:HKD
2023-09-30
0001809616
2022-10-01
2023-09-30
0001809616
upc:MrXiboLiuMember
upc:YunnanFaxiPharmaceuticalsCoLtdMember
2022-09-26
0001809616
2022-09-26
2022-09-26
0001809616
2022-09-26
0001809616
us-gaap:BuildingMember
2023-09-30
0001809616
us-gaap:MachineryAndEquipmentMember
2024-03-31
0001809616
us-gaap:MachineryAndEquipmentMember
2023-09-30
0001809616
us-gaap:AutomobilesMember
2024-03-31
0001809616
us-gaap:AutomobilesMember
2023-09-30
0001809616
upc:OfficeAndElectricEquipmentMember
2024-03-31
0001809616
upc:OfficeAndElectricEquipmentMember
2023-09-30
0001809616
upc:LandUseRightsMember
2024-03-31
0001809616
upc:LandUseRightsMember
2023-09-30
0001809616
us-gaap:SoftwareDevelopmentMember
2024-03-31
0001809616
us-gaap:SoftwareDevelopmentMember
2023-09-30
0001809616
us-gaap:ConstructionInProgressMember
2021-06-25
0001809616
upc:ChenyuanMember
2024-03-31
0001809616
us-gaap:ConstructionInProgressMember
2024-03-31
0001809616
us-gaap:ConstructionInProgressMember
upc:ChenyuanMember
2024-03-31
0001809616
us-gaap:ConstructionInProgressMember
2023-10-01
2024-03-31
0001809616
upc:CapitalExpenditureOnCIPMember
2024-03-31
0001809616
upc:JiangxiYueshangMember
srt:ChiefExecutiveOfficerMember
2021-05-06
0001809616
2021-05-06
0001809616
2021-05-06
2021-05-06
0001809616
upc:MrGangLaiMember
2021-05-06
2021-05-06
0001809616
2021-05-01
2021-05-06
0001809616
upc:JiangxiYueshangMember
2024-03-31
2024-03-31
0001809616
2023-03-13
0001809616
upc:WorkingCapitalLoanMember
2023-03-13
2023-03-13
0001809616
upc:LRCBankMember
2023-06-15
0001809616
upc:WorkingCapitalLoanMember
upc:LRCBankMember
2023-06-15
2023-06-15
0001809616
upc:JiangxiLulingRuralCommercialBankMember
2023-06-15
0001809616
upc:JiangxiUniverseMember
2023-06-15
0001809616
upc:JiangxiUniverseMember
2023-06-15
2023-06-15
0001809616
upc:WorkingCapitalLoanMember
upc:JiangxiUniverseMember
2023-06-15
2023-06-15
0001809616
upc:MrGangLaiMember
2023-06-15
0001809616
2023-05-05
0001809616
upc:WorkingCapitalLoanMember
2023-05-05
2023-05-05
0001809616
upc:JiangxiLulingRuralCommercialBankMember
2023-05-05
0001809616
2023-07-24
0001809616
upc:WorkingCapitalLoanMember
2023-07-24
2023-07-24
0001809616
upc:JiangxiLulingRuralCommercialBankLRCBankMember
2024-03-31
0001809616
upc:JiangxiLulingRuralCommercialBankLRCBankMember
2023-09-30
0001809616
upc:BankOfCommunicationsCoLtdMember
2024-03-31
0001809616
upc:BankOfCommunicationsCoLtdMember
2023-09-30
0001809616
upc:ZhujiangRuralBankMember
2024-03-31
0001809616
upc:ZhujiangRuralBankMember
2023-09-30
0001809616
upc:BeijingBankMember
2024-03-31
0001809616
upc:BeijingBankMember
2023-09-30
0001809616
upc:LRCBankMember
2023-11-23
0001809616
upc:LRCBankMember
2024-03-31
0001809616
upc:LRCBankMember
2023-09-30
0001809616
upc:JiangxiYueshangMember
2024-03-31
2024-03-31
0001809616
upc:MrGangLaiMember
2022-01-13
0001809616
upc:GuangzhouNingjingMember
2024-03-31
0001809616
upc:GuangzhouNingjingMember
2023-09-30
0001809616
upc:MrGangLaiMember
2023-10-01
2024-03-31
0001809616
upc:MrYajunHuMember
2023-10-01
2024-03-31
0001809616
upc:GuangzhouNingjingInvestmentCoLtdMember
2023-10-01
2024-03-31
0001809616
upc:MrYajunHuMember
2024-03-31
0001809616
upc:MrYajunHuMember
2023-09-30
0001809616
upc:MrGangLaiMember
2024-03-31
0001809616
upc:MrGangLaiMember
2023-09-30
0001809616
upc:NoSingleCustomerrMember
us-gaap:SalesRevenueNetMember
us-gaap:CustomerConcentrationRiskMember
2023-10-01
2024-03-31
0001809616
upc:CustomerOneMember
us-gaap:SalesRevenueNetMember
us-gaap:CustomerConcentrationRiskMember
2022-10-01
2023-03-31
0001809616
upc:TopTenCustomersMember
srt:MinimumMember
us-gaap:SalesRevenueNetMember
us-gaap:CustomerConcentrationRiskMember
2023-10-01
2024-03-31
0001809616
upc:TopTenCustomersMember
srt:MaximumMember
us-gaap:SalesRevenueNetMember
us-gaap:CustomerConcentrationRiskMember
2022-10-01
2023-03-31
0001809616
upc:CustomerMember
us-gaap:SalesRevenueNetMember
us-gaap:CustomerConcentrationRiskMember
upc:GubenYanlingPillMember
2023-10-01
2024-03-31
0001809616
upc:CustomerMember
us-gaap:SalesRevenueNetMember
us-gaap:CustomerConcentrationRiskMember
upc:GubenYanlingPillMember
2022-10-01
2023-03-31
0001809616
upc:CustomerMember
us-gaap:AccountsReceivableMember
us-gaap:CustomerConcentrationRiskMember
2022-10-01
2023-09-30
0001809616
upc:CustomerMember
us-gaap:AccountsReceivableMember
us-gaap:CustomerConcentrationRiskMember
2021-10-01
2022-09-30
0001809616
upc:PurchaseMember
us-gaap:CustomerConcentrationRiskMember
upc:SupplierOneMember
2023-10-01
2024-03-31
0001809616
upc:PurchaseMember
us-gaap:CustomerConcentrationRiskMember
upc:SupplierTwoMember
2023-10-01
2024-03-31
0001809616
upc:PurchaseMember
us-gaap:CustomerConcentrationRiskMember
upc:SupplierOneMember
2022-10-01
2023-03-31
0001809616
upc:UniverseINCMember
us-gaap:CommonStockMember
2019-12-11
0001809616
upc:UniverseINCMember
us-gaap:CommonStockMember
2020-08-07
0001809616
upc:UniverseINCMember
us-gaap:CommonStockMember
2020-08-07
2020-08-07
0001809616
upc:UniverseINCMember
2020-08-07
0001809616
upc:UniverseINCMember
us-gaap:CommonStockMember
2023-10-01
2024-03-31
0001809616
upc:UniverseINCMember
2024-03-31
0001809616
srt:MinimumMember
us-gaap:PreferredStockMember
2023-07-03
0001809616
srt:MaximumMember
us-gaap:CommonStockMember
2023-07-03
0001809616
srt:MaximumMember
us-gaap:PreferredStockMember
2023-07-03
0001809616
2023-07-03
2023-07-03
0001809616
srt:MinimumMember
us-gaap:CommonStockMember
upc:ResolveRatioThreeMember
2023-07-27
0001809616
srt:MaximumMember
upc:CommonStockOneMember
2023-07-27
0001809616
srt:MinimumMember
upc:CommonStockOneMember
2023-07-27
0001809616
srt:MinimumMember
us-gaap:PreferredStockMember
2023-07-27
0001809616
srt:MaximumMember
us-gaap:PreferredStockMember
2023-07-27
0001809616
upc:UnderwriterWarrantsMember
2024-03-31
0001809616
us-gaap:CommonStockMember
upc:UnderwriterWarrantsMember
2024-03-31
0001809616
upc:UnderwriterWarrantsMember
2023-10-01
2024-03-31
0001809616
upc:StatutoryReserveAndRestrictedNetAssetsMember
2023-10-01
2024-03-31
0001809616
upc:StatutoryReserveAndRestrictedNetAssetsMember
2024-03-31
0001809616
upc:StatutoryReserveAndRestrictedNetAssetsMember
2023-09-30
2023-09-30
0001809616
2024-03-31
2024-03-31
0001809616
upc:MrGangLaiMember
2021-05-06
0001809616
upc:ZhujiangRuralBankMember
us-gaap:SubsequentEventMember
2024-04-23
0001809616
upc:ZhujiangRuralBankMember
us-gaap:SubsequentEventMember
2024-04-23
2024-04-23
0001809616
upc:LRCBankMember
us-gaap:SubsequentEventMember
2024-04-26
0001809616
upc:LRCBankMember
us-gaap:SubsequentEventMember
2024-04-26
2024-04-26
0001809616
upc:WorkingCapitalMember
upc:LRCBankMember
us-gaap:SubsequentEventMember
2024-04-26
2024-04-26
0001809616
srt:ScenarioForecastMember
upc:MrGangLaiMember
2024-06-16
0001809616
srt:ScenarioForecastMember
upc:MrGangLaiMember
2024-06-16
2024-06-16
0001809616
srt:ScenarioForecastMember
upc:WorkingCapitalMember
upc:MrGangLaiMember
2024-06-16
2024-06-16
0001809616
srt:ScenarioForecastMember
upc:BeijingBankMember
2024-07-03
0001809616
srt:ScenarioForecastMember
upc:BeijingBankMember
2024-07-03
2024-07-03
0001809616
srt:ScenarioForecastMember
2024-07-15
2024-07-15
0001809616
srt:ScenarioForecastMember
us-gaap:CommonStockMember
2024-07-15
0001809616
us-gaap:ParentMember
2024-03-31
0001809616
us-gaap:ParentMember
2023-09-30
0001809616
us-gaap:ParentMember
2023-10-01
2024-03-31
0001809616
us-gaap:ParentMember
2022-10-01
2023-03-31
0001809616
us-gaap:ParentMember
2022-09-30
0001809616
us-gaap:ParentMember
2023-03-31
iso4217:USD
iso4217:USD
xbrli:shares
xbrli:shares
xbrli:pure
iso4217:CNY
utr:sqm
Exhibit 99.2
MANAGEMENT’S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATION
The following discussion and analysis of our
financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements
and related notes that appear elsewhere in the report on Form 6-K of which this document is a part. In addition to historical consolidated
financial information, the following discussion contains forward-looking statements that reflect our plans, estimates, and beliefs. Our
actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute
to these differences include those discussed below and elsewhere in our annual report on Form 20-F for the fiscal year ended September
30, 2023, particularly under the caption “Item 3. Key Information—D. Risk Factors.”
Overview
Through its subsidiaries (the “PRC operating
entities”) in the People’s Republic of China (“China” or the “PRC”), Universe Pharmaceuticals INC
(the “Company,” “we,” “our” and “us”) is a pharmaceutical company specializing in the
development, manufacturing, marketing and sale of traditional Chinese medicine derivatives (“TCMD”) products targeted to the
elderly to address their physical conditions in the aging process and to promote their general well-being. We have registered and obtained
approval for 26 varieties of TCMD products from the National Medical Products Administration (the “NMPA”), and we currently
produce 13 varieties of TCMD products and sell them in 261 cities in 30 provinces in China as of the date of this report. In addition,
we also sell biomedical drugs, medical instruments, traditional Chinese medicine pieces (“TCMPs”) and dietary supplements
manufactured by third-party pharmaceutical companies (collectively referred to as “third-party products”).
Our major customers are pharmaceutical companies,
hospitals, clinics and drugstore chains, primarily located in Jiangxi Province, Jiangsu Province, Guangdong Province, Hubei Province,
Fujian Province, Guangxi Province and Shandong Province, and 23 other provinces in China.
Key Financial Performance Indicators
In assessing our financial performance, we consider
a variety of financial performance measures, including principal growth in net revenue and gross profit, our ability to control costs
and operating expenses to improve our operating efficiency and net income. Our review of these indicators facilitates timely evaluation
of the performance of our business and effective communication of results and key decisions, allowing our business to respond promptly
to competitive market conditions and different demands and preferences from our customers. The key measures that we use to evaluate the
performance of our business are set forth below.
Net Revenue
Our revenue is reported net of all value added
taxes (“VAT”). Our products are sold with no right of return and we do not provide other credits or sales incentive to customers.
Our revenue is driven by sales volume, selling price, and mix of products sold.
| |
For the six Months Ended March 31, | | |
Variance | |
| |
2024 | | |
2023 | | |
% | |
Revenue from sales of self-manufactured TCMD products | |
| 53.3 | % | |
| 50.8 | % | |
| (6.5 | )% |
Revenue from sales of third-party products | |
| 46.7 | % | |
| 49.2 | % | |
| 6.5 | % |
Total revenue | |
| 100.0 | % | |
| 100.0 | % | |
| | |
| |
| | | |
| | | |
| | |
Sales volume by unit- TCMD products | |
| 6,097,325 | | |
| 7,961,244 | | |
| (23.4 | )% |
Sales volume by unit- third party products | |
| 4,014,841 | | |
| 5,727,501 | | |
| (29.9 | )% |
Total sales volume | |
| 10,112,166 | | |
| 13,688,745 | | |
| (26.1 | )% |
| |
| | | |
| | | |
| | |
Average selling price per unit- TCMD products | |
$ | 1.13 | | |
$ | 1.18 | | |
| (4.2 | )% |
Average selling price per unit- Third-party products | |
$ | 1.50 | | |
$ | 1.59 | | |
| (5.7 | )% |
Revenues from sales of TCMD products manufactured
by us accounted for 53.3% and 50.8% of our total revenues for the six months ended March 31, 2024 and 2023, respectively. The 13 TCMD
products manufactured by us fall into two categories: (i) treatment and relief for common chronic health conditions in the elderly designed
to achieve physical wellness and longevity (the “Chronic Condition Treatments”) and (ii) cold and flu medications. Our Chronic
Condition Treatments primarily include Guben Yanling Pill, Shenrong Weisheng Pill, Quanlu Pill, Yangxue Danggui Syrup, Wuzi Yanzong Oral
Liquid, Fengtong Medicinal Liquor, Shenrong Medicinal Liquor, Qishe Medicinal Liquor, Fengshitong Medicinal Liquor, and Shiquan Dabu Medicinal
Liquor, and our cold and flu medications primarily include Paracetamol Granule for Children, Isatis Root Granule and Qiangli Pipa Syrup.
In order to diversify our product offerings and
product mix, in addition to selling our self-manufactured TCMD products, we also sell products manufactured by third-party pharmaceutical
companies, including (i) biomedical drugs, such as liquid glucose, prednisolone, and citicoline, (ii) medical instruments, such as drug-eluting
stents, surgical tubes and syringes, (iii) TCMPs, such as red sage tables, Longdan Xiegan pills, and Chinese skullcap capsules, and (iv)
dietary supplements, such as vitamins, probiotic powder, and calcium tablets. Revenues from sales of third-party products accounted for
46.7% and 49.2% of our total revenues for the six months ended March 31, 2024 and 2023, respectively.
Gross Profit
Gross profit is equal to net revenue minus cost
of goods sold. Cost of goods sold primarily includes inventory costs (raw materials, labor, packaging cost, depreciation and amortization,
third-party products purchase price, freight costs and overhead). Cost of goods sold generally changes as our production costs change,
as these are affected by factors including the market price of raw materials, labor productivity, or the purchase price of third-party
products, and as the customer and product mix changes. Our cost of revenues accounted for 73.8% and 66.8% of our total revenue for the
six months ended March 31, 2024 and 2023, respectively. We expect our cost of revenues to increase as we further expand our operations
in the foreseeable future.
Our gross margin was 26.2% for the six months
ended March 31, 2024, a decrease of 7.0% from the gross margin of 33.2% in the six months ended March 31, 2023, due to a decrease in the
average selling price of our TCMD products and third-party products by 4.2% and 5.7%, respectively, as well as an increase in the average
per unit cost of our TCMD products by 10.5%.
Operating Expenses
Our operating expenses consist of selling expenses,
general and administrative expenses and research and development expenses.
Our selling expenses primarily include salary
and welfare benefit expenses paid to our sales personnel, advertising expenses to increase the awareness of our brand, shipping and delivery
expenses, expenses incurred for our business travel, meals and other sales promotion and marketing activities related expenses. Our selling
expenses accounted for 31.5% and 12.6% of our total revenue for the six months ended March 31, 2024 and 2023, respectively. We expect
our overall selling expenses, including but not limited to, advertising expenses and brand promotion expenses and salaries, to increase
in the foreseeable future and facilitate the growth of our business, especially when we continue to expand our business and promote our
products to customers located at extended geographic areas.
Our general and administrative expenses primarily
consist of employee salaries, welfare and insurance expenses, depreciation, bad debt reserve expenses, inspection and maintenance expenses,
office supply and utility expenses, business travel and meals expenses, land and property taxes and professional service expenses. General
and administrative expenses accounted for 7.5% of our revenue for the six months ended March 31, 2024 and 2023. We expect our general
and administrative expenses, including, but not limited to, salaries and business consulting expenses, to increase in the foreseeable
future, as we plan to hire additional personnel and incur additional expenses in connection with the expansion of our business operations.
The Chinese patent medicine industry is characterized
by rapid and frequent changes in customer demand and launches of new products. If we do not launch new products or improve our existing
products to meet the changing demands of our customers in a timely manner, some of our products could become uncompetitive in the market,
thereby adversely affecting on our revenues and operating results. Our research and development expenses primarily consist of salaries,
welfare and insurance expenses paid to our employees involved in the research and development activities, materials and supplies used
in the development and testing of new TCMD products, depreciation, and other miscellaneous expenses. Research and development expenses
accounted for 0.7% and 12.3% of our revenue for the six months ended March 31, 2024 and 2023, respectively. As we continue to develop
new products and diversify our product offerings to satisfy customer demand, we expect our research and development expenses to increase
in the foreseeable future.
Financial Results for the Six Months Ended
March 31, 2024 Compared to the Six Months Ended March 31, 2023
The following table summarizes the results of
our operations during the six months ended March 31, 2024 and 2023, respectively, and provides information regarding the dollar and percentage
increase or (decrease) during such periods.
| |
For the six Months Ended March 31, | |
| |
2024 | | |
2023 | | |
Variance | |
| |
Amount | | |
% of revenue | | |
Amount | | |
% of revenue | | |
Amount | | |
% | |
| |
| | |
| | |
| | |
| | |
| | |
| |
REVENUE | |
$ | 12,884,370 | | |
| 100.0 | % | |
$ | 18,467,186 | | |
| 100.0 | % | |
$ | (5,582,816 | ) | |
| (30.2 | )% |
COST OF REVENUE | |
| 9,515,039 | | |
| 73.8 | % | |
| 12,339,044 | | |
| 66.8 | % | |
| (2,824,005 | ) | |
| (22.9 | )% |
GROSS PROFIT | |
| 3,369,331 | | |
| 26.2 | % | |
| 6,128,142 | | |
| 33.2 | % | |
| (2,758,811 | ) | |
| (45.0 | )% |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
OPERATING EXPENSES | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Selling expenses | |
| 4,054,357 | | |
| 31.5 | % | |
| 2,330,508 | | |
| 12.6 | % | |
| 1,723,849 | ) | |
| 74.0 | % |
General and administrative expenses | |
| 968,608 | | |
| 7.5 | % | |
| 1,380,053 | | |
| 7.5 | % | |
| (411,445 | ) | |
| (29.8 | )% |
Research and development expenses | |
| 86,503 | | |
| 0.7 | % | |
| 2,268,335 | | |
| 12.3 | % | |
| (2,181,832 | ) | |
| (96.2 | )% |
Total operating expenses | |
| 5,109,468 | | |
| 39.7 | % | |
| 5,978,896 | | |
| 32.4 | % | |
| (869,428 | ) | |
| (14.5 | )% |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
INCOME FROM OPERATIONS | |
| (1,740,137 | ) | |
| (13.5 | )% | |
| 149,246 | | |
| 0.8 | % | |
| (1,889,383 | ) | |
| (1,266.0 | )% |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
OTHER INCOME (EXPENSE) | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Interest expense, net | |
| (136,613 | ) | |
| (1.1 | )% | |
| (74,569 | ) | |
| (0.4 | )% | |
| (62,044 | ) | |
| 83.2 | % |
Other income, net | |
| 152,027 | | |
| 1.2 | % | |
| 17,323 | | |
| 0.1 | % | |
| 134,704 | | |
| 777.6 | % |
Realized (loss) gain on short-term investments | |
| (3,094,084 | ) | |
| (24.0 | )% | |
| 166,931 | | |
| 0.9 | % | |
| (3,261,015 | ) | |
| (1,953.5 | )% |
Change in fair value of short-term investments | |
| (7,617,502 | ) | |
| (59.1 | )% | |
| - | | |
| - | % | |
| (7,617,502 | ) | |
| - | % |
Total other (loss) income, net | |
| (10,696,172 | ) | |
| (83.0 | )% | |
| 109,685 | | |
| 0.6 | % | |
| (10,805,857 | ) | |
| (9,851.7 | )% |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
(LOSS) INCOME BEFORE INCOME TAX
PROVISION | |
| (12,436,309 | ) | |
| (96.5 | )% | |
| 258,931 | | |
| 1.4 | % | |
| (12,695,240 | ) | |
| (4,902.9 | )% |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
PROVISION FOR INCOME TAXES | |
| 665,148 | | |
| 5.2 | % | |
| 974,358 | | |
| 5.3 | % | |
| (309,210 | ) | |
| (31.7 | )% |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
NET LOSS | |
$ | (13,101,457 | ) | |
| (101.7 | )% | |
$ | (715,427 | ) | |
| (3.9 | )% | |
$ | (12,386,030 | ) | |
| 1,731.3 | % |
Revenues. We currently produce
and sell 13 varieties of TCMD products and also sell products manufactured by third-party pharmaceutical companies, to our customers.
| |
For the six months ended March 31, | |
| |
2024 | | |
2023 | | |
Change | |
| |
Amount | | |
Amount | | |
Amount | | |
% | |
| |
| | |
| | |
| | |
| |
Revenue - TCMD products sales | |
$ | 6,870,591 | | |
$ | 9,374,312 | | |
$ | (2,503,721 | ) | |
| (26.7 | )% |
Revenue – third-party products sales | |
| 6,013,779 | | |
| 9,092,874 | | |
| (3,079,095 | ) | |
| (33.9 | )% |
Total revenue | |
$ | 12,884,370 | | |
$ | 18,467,186 | | |
$ | (5,582,816 | ) | |
| (30.2 | )% |
Our revenues decreased by $5,582,816, or 30.2%,
to $12,884,370 for the six months ended March 31, 2024, from $18,467,186 for the six months ended March 31, 2023.
Revenue from sales of our TCMD products
Sales of TCMD products decreased by $2,503,721,
or 26.7%, to $6,870,591 for the six months ended March 31, 2024, from $9,374,312 for the six months ended March 31, 2023. The decrease
in the sales of our TCMD product was due to the following specific reasons:
|
a) |
Global economic slowdown has led to a decline in customers’ spending power, and sales volume of our TCMD products decreased by 23.4%, to 6,097,325 units sold in the six months ended March 31, 2024, from 7,961,244 units sold in the six months ended March 31, 2023. |
|
b) |
The average selling price of our TCMD products decreased by $0.05 per unit, or 4.2%, to $1.13 per unit in the six months ended March 31, 2024, from $1.18 per unit in the six months ended March 31, 2023, due to a change in product mix. |
|
c) |
The exchange rate between RMB and US$ was US$1.00 to RMB6.9761 in the six months ended March 31, 2023 as compared to US$1.00 to RMB7.2064 in the six months ended March 31, 2024. The depreciation of RMB against US$ had a 3.3% negative impact on our reported revenues. |
Revenue from sales of third-party products
Sales of third-party products decreased by $3,079,095,
or 33.9%, to $6,013,779 for the six months ended March 31, 2024, from $9,092,874 for the six months ended March 31, 2023. Sales volume
of third-party products decreased by 29.9%, to 4,014,841 units sold in the six months ended March 31, 2024, from 5,727,501 units sold
in the six months ended March 31, 2023. The average selling price of third-party products decreased by $0.09 per unit, or 5.7%, to $1.50
per unit in the six months ended March 31, 2024, from $1.59 per unit in the six months ended March 31, 2023, due to a change in product
mix and the 3.3% negative impact from foreign currency fluctuation as discussed above.
Cost of Revenues. Our cost
of revenues primarily consists of inventory costs (raw materials, labor, packaging cost, depreciation and amortization, third-party products
purchase price, freight costs and overhead) and business tax. Cost of revenues generally changes as our production costs change, which
are affected by factors including the market price of raw materials, labor productivity, and the purchase price of third-party products,
and as the customer and product mix changes.
| |
For the six months ended March 31, | |
| |
2024 | | |
2023 | | |
Change | |
| |
Amount | | |
Amount | | |
Amount | | |
% | |
| |
| | |
| | |
| | |
| |
Cost of revenue- TCMD products | |
$ | 5,602,807 | | |
$ | 6,617,444 | | |
$ | (1,014,637 | ) | |
| (15.3 | )% |
Cost of revenue- third-party products | |
| 3,912,232 | | |
| 5,721,600 | | |
| (1,809,368 | ) | |
| (31.6 | )% |
Total cost of revenue | |
$ | 9,515,039 | | |
$ | 12,339,044 | | |
$ | (2,824,005 | ) | |
| (22.9 | )% |
Cost of revenues decreased by $2,824,005, or 22.9%,
to $9,515,039 for the six months ended March 31, 2024, from $12,339,044 for the six months ended March 31, 2023, due to a decrease in
sales volume.
Cost of revenues of TCMD products
Cost of revenues of TCMD products accounted for
58.9% and 53.6% of our total costs of revenues for the six months ended March 31, 2024 and 2023, respectively. Cost of revenues of TCMD
products decreased by $1,014,637, or 15.3%, from $6,617,444 in the six months ended March 31, 2023 to $5,602,807 in the six months ended
March 31, 2024. The decrease in cost of revenues of our TCMD products was due to the following reasons:
|
(1) |
Sales volume of our TCMD products decreased by 23.4%, to 6,097,325 units sold in the six months ended March 31, 2024, from 7,961,244 units sold in the six months ended March 31, 2023. |
|
(2) |
In the summer of 2023, a severe flood in Anhui Province and Hubei Province of China, which are two main producing areas of traditional Chinese medicinal materials, led to a decrease in the supply of such materials, and the prices of the traditional Chinese medicine raw materials increased during the six months ended March 31, 2024. The average per unit cost of our TCMD products increased by $0.09, or 10.5%, from $0.83 per unit in the six months ended March 31, 2023 to $0.92 per unit in the six months ended March 31, 2024. |
|
(3) |
The 3.3% negative impact from foreign currency fluctuation as discussed above. |
Cost of revenues of third-party products
Cost of revenues of third-party products accounted
for 41.1% and 46.4% of our total costs of revenues for the six months ended March 31, 2024 and 2023, respectively. Cost of revenues of
third-party products decreased by $1,809,368, or 31.6%, from $5,721,600 in the six months ended March 31, 2023 to $3,912,232 in the six
months ended March 31, 2024, because of decrease in sales volume of third-party products by 29.9% from 5,727,501 units sold in the six
months ended March 31, 2023 to 4,014,841 units sold in the six months ended March 31, 2024. The average per unit cost of third-party products
decreased slightly by $0.03 per unit, or 2.5%, from $1.00 per unit in the six months ended March 31, 2023 to $0.97 per unit in the six
months ended March 31, 2024, due to change in product mix and the 3.3% negative impact from foreign currency fluctuation as discussed
above.
Gross profit
Our gross profit decreased by $2,758,811 to $3,369,331
for the six months ended March 31, 2024, from $6,128,142 for the six months ended March 31, 2023. Our margin decreased by 7.0% to 26.2%
for the six months ended March 31, 2024, from 33.2% for the six months ended March 31, 2023.
| |
For the six months ended March 31, | |
| |
2024 | | |
2023 | | |
Change | |
| |
Amount | | |
Amount | | |
Amount | | |
% | |
| |
| | |
| | |
| | |
| |
Gross profit- TCMD products | |
$ | 1,267,784 | | |
$ | 2,756,868 | | |
$ | (1,489,084 | ) | |
| (54.0 | )% |
Gross profit- third-party products | |
| 2,101,547 | | |
| 3,371,274 | | |
| (1,269,727 | ) | |
| (37.7 | )% |
Total gross profit | |
$ | 3,369,331 | | |
$ | 6,128,142 | | |
$ | (2,758,811 | ) | |
| (45.0 | )% |
| |
| | | |
| | | |
| | | |
| | |
Gross margin- TCMD products | |
| 18.5 | % | |
| 29.4 | % | |
| | | |
| (11.0 | )% |
Gross margin- third party products | |
| 34.9 | % | |
| 37.1 | % | |
| | | |
| (2.2 | )% |
Total gross margin | |
| 26.2 | % | |
| 33.2 | % | |
| | | |
| (7.0 | )% |
| |
| | | |
| | | |
| | | |
| | |
Average selling price per unit- TCMD products | |
$ | 1.13 | | |
$ | 1.18 | | |
$ | (0.05 | ) | |
| (4.2 | )% |
Average cost per unit- TCMD products | |
$ | 0.92 | | |
$ | 0.83 | | |
$ | 0.09 | | |
| 10.5 | % |
| |
| | | |
| | | |
| | | |
| | |
Average selling price per unit- third party products | |
$ | 1.50 | | |
$ | 1.59 | | |
$ | (0.09 | ) | |
| (5.7 | )% |
Average cost per unit - third party products | |
$ | 0.97 | | |
$ | 1.00 | | |
$ | (0.02 | ) | |
| (2.5 | )% |
Gross profit from the sales of our TCMD products
decreased by $1,489,084, or 54.0%, from $2,756,868 in the six months ended March 31, 2023 to $1,267,784 in the six months ended March
31, 2024, and the gross margin of our TCMD products decreased by 11.0 percentage point, from 29.4% in the six months ended March 31, 2023
to 18.5% in the six months ended March 31, 2024. The decrease in our gross profit from the sales of TCMD products was affected by the
decrease in sales volume, decrease in average unit selling price, and increase in the average per unit cost.
Gross profit from third-party product sales decreased
by $1,269,727, or 37.7%, from $3,371,274 in the six months ended March 31, 2023 to $2,101,547 in the six months ended March 31, 2024,
while the gross margin of third-party product sales slightly decreased by 2.2%, from 37.1% in the six months ended March 31, 2023 to 34.9%
in the six months ended March 31, 2024. The decrease in our gross profit from third-party products was affected by the decrease in sales
volume and the average unit selling price, and partially offset by the decrease in the average per unit cost.
Operating expenses
The following table sets forth the breakdown of
our operating expenses for the six months ended March 31, 2024 and 2023:
| |
For the six months ended March 31, | |
| |
2024 | | |
2023 | | |
Variance | |
| |
Amount | | |
% of revenue | | |
Amount | | |
% of revenue | | |
Amount | | |
% | |
Total revenue | |
$ | 12,884,370 | | |
| 100.0 | % | |
$ | 18,467,186 | | |
| 100.0 | % | |
$ | (5,582,816 | ) | |
| (30.2 | )% |
Operating expenses: | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Selling expenses | |
| 4,054,357 | | |
| 31.5 | % | |
| 2,330,508 | | |
| 12.6 | % | |
| 1,723,849 | | |
| 74.0 | % |
General and administrative expenses | |
| 968,608 | | |
| 7.5 | % | |
| 1,380,053 | | |
| 7.5 | % | |
| (411,445 | ) | |
| (29.8 | )% |
Research and development expenses | |
| 86,503 | | |
| 0.7 | % | |
| 2,268,335 | | |
| 12.3 | % | |
| (2,181,832 | ) | |
| (96.2 | )% |
Total operating expenses | |
$ | 5,109,468 | | |
| 39.7 | % | |
$ | 5,978,896 | | |
| 32.4 | % | |
$ | (869,428 | ) | |
| (14.5 | )% |
Selling expenses
Our selling expenses primarily include salaries
and welfare benefit expenses paid to our sales personnel, advertising expenses to increase our brand awareness, shipping and delivery
expenses, expenses incurred for our business travel, meals and other sales promotion and marketing activities related expenses.
| |
For the six months ended March 31, | |
| |
2024 | | |
2023 | | |
Variance | |
| |
Amount | | |
% | | |
Amount | | |
% | | |
Amount | | |
% | |
| |
| | |
| | |
| | |
| | |
| | |
| |
Salary and employee benefit expenses | |
$ | 461,859 | | |
| 11.4 | % | |
$ | 349,755 | | |
| 15.0 | % | |
$ | 112,104 | | |
| 32.1 | % |
Advertising expenses | |
| 2,773,300 | | |
| 68.4 | % | |
| 1,340,368 | | |
| 57.5 | % | |
| 1,432,932 | | |
| 106.9 | % |
Shipping and delivery expenses | |
| 612,373 | | |
| 15.1 | % | |
| 559,882 | | |
| 24.0 | % | |
| 52,491 | | |
| 9.4 | % |
Business travel and meals expenses | |
| 106,512 | | |
| 2.6 | % | |
| 71,535 | | |
| 3.1 | % | |
| 34,977 | | |
| 48.9 | % |
Other sales promotion related expenses | |
| 100,313 | | |
| 2.5 | % | |
| 8,968 | | |
| 0.4 | % | |
| 91,345 | | |
| 1018.6 | % |
Total selling expenses | |
$ | 4,054,357 | | |
| 100.0 | % | |
$ | 2,330,508 | | |
| 100.0 | % | |
$ | 1,723,849 | | |
| 74.0 | % |
Selling expenses increased by $1,723,849, or 74.0%,
to $4,054,357 for the six months ended March 31, 2024, from $2,330,508 for the six months ended March 31, 2023, primarily attributable
to (i) an increase in advertising expenses by $1,432,932, from $1,340,368 in the six months ended March 31, 2023, to $2,773,300 in the
six months ended March 31, 2024. The Company entered into advertising service agreement with Health Headline to promote its brand on the
Health Headline’s website and mobile app, increased publicity efforts for its products and brand, and the advertising expenses increased
significantly during the six months ended March 31, 2024; and (ii) an increase in salary and employee benefit expenses by $112,104, or
32.1%, as the Company recruited 10 new employees in the marketing department to promote sales of its products.
General and Administrative Expenses
Our general and administrative expenses primarily
consist of employee salaries, welfare and insurance expenses, depreciation, bad debt reserve expenses, inspection and maintenance expenses,
office supply and utility expenses, business travel and meals expenses, land and property taxes and professional service expenses.
| |
For the six months ended March 31, | |
| |
2024 | | |
2023 | | |
Variance | |
| |
Amount | | |
% | | |
Amount | | |
% | | |
Amount | | |
% | |
| |
| | |
| | |
| | |
| | |
| | |
| |
Salary and employee benefit expense | |
$ | 372,820 | | |
| 38.5 | % | |
$ | 305,163 | | |
| 22.1 | % | |
$ | 67,657 | | |
| 22.2 | % |
Depreciation and amortization | |
| 112,905 | | |
| 11.7 | % | |
| 91,279 | | |
| 6.6 | % | |
| 21,626 | | |
| 23.7 | % |
Bad debt reserve expenses (recovery) | |
| (265,530 | ) | |
| (27.4 | )% | |
| 0 | | |
| 0.0 | )% | |
| (265,530 | ) | |
| - | % |
Land and property tax | |
| (11,317 | ) | |
| (1.2 | )% | |
| 48,739 | | |
| 3.5 | % | |
| (60,056 | ) | |
| (123.2 | )% |
Office supply and utility expense | |
| 121,054 | | |
| 12.5 | % | |
| 338,735 | | |
| 24.5 | % | |
| (217,681 | ) | |
| (64.3 | )% |
Transportation, business travel and meals expense | |
| 72,084 | | |
| 7.4 | % | |
| 51,530 | | |
| 3.7 | % | |
| 20,554 | | |
| 39.9 | % |
Consulting fee | |
| 489,769 | | |
| 50.6 | % | |
| 503,046 | | |
| 36.5 | % | |
| (13,277 | ) | |
| (2.6 | )% |
Inspection and maintenance fee | |
| 7,908 | | |
| 0.8 | % | |
| 21,701 | | |
| 1.6 | % | |
| (13,793 | ) | |
| (63.6 | )% |
Stamp tax and other expenses | |
| 68,915 | | |
| 7.1 | % | |
| 19,860 | | |
| 1.5 | % | |
| 49,055 | | |
| 247.0 | % |
Total general and administrative expenses | |
$ | 968,608 | | |
| 100.0 | % | |
$ | 1,380,053 | | |
| 100.0 | % | |
$ | (411,445 | ) | |
| (29.8 | )% |
General and administrative expenses decreased
by $411,445, or 29.8%, to $968,608 for the six months ended March 31, 2024 from $1,380,053 for the six months ended March 31, 2023, primarily
attributable to (i) bad debt reserve recovery of $265,530 for the six months ended March 31, 2024, because the Company accrued less bad
debt expenses based on its assessment of the collectability of the accounts receivable and advance to suppliers; and (ii) a decrease in
office supply and utility expense by $217,681 due to cost savings.
Research and development expenses
Our research and development expenses primarily
consist of salaries, welfare and insurance expenses paid to our employees involved in the research and development activities, materials
and supplies used in the development and testing new TCMD products, depreciation and other miscellaneous expenses.
| |
For the six months ended March 31, | |
| |
2024 | | |
2023 | | |
Variance | |
| |
Amount | | |
% | | |
Amount | | |
% | | |
Amount | | |
% | |
Salary and employee benefit expenses to research and development staff | |
$ | 74,703 | | |
| 86.4 | % | |
$ | 74,073 | | |
| 3.3 | % | |
$ | 630 | | |
| 0.9 | % |
Materials used in research and development activities | |
| - | | |
| 0.0 | % | |
| 666,765 | | |
| 29.4 | % | |
| (666,765 | ) | |
| (100.0 | )% |
Expenditure on new product development | |
| - | | |
| 0.0 | % | |
| 1,505,144 | | |
| 66.4 | % | |
| (1,505,144 | ) | |
| (100.0 | )% |
Depreciation and others | |
| 11,800 | | |
| 13.6 | % | |
| 22,353 | | |
| 0.9 | % | |
| (10,553 | ) | |
| (47.2 | )% |
Total research and development expenses | |
$ | 86,503 | | |
| 100.0 | % | |
$ | 2,268,335 | | |
| 100.0 | % | |
$ | (2,181,832 | ) | |
| (96.2 | )% |
Research and development expenses decreased by
$2,181,832, or 96.2%, to $86,503 for the six months ended March 31, 2024, from $2,268,335 for the six months ended March 31, 2023, primarily
attributable to (i) a decrease in development expenditure on improving production process of the Company’s Chinese medicine products
in the amount of $1,505,144. The Company entered into several cooperative agreements with external academic and research institutions
to jointly conduct development of eight production process to improve production efficiency and product quality, with activities beginning
in August 2022, and incurred significant amount of research and development expense in connection with such efforts during the six months
ended March 31, 2023. These development activities were completed and results were integrated in production in September 2023, and no
such expenses incurred during the six months ended March 31, 2024; and (ii) a decrease in the materials used in the research and development
activities by $666,765 in connection with development activities on improving production process.
Other income (expenses), net
Total other expenses, net was $10,696,172 for
the six months ended March 31, 2024, compared to total other income of $109,685 for the six months ended March 31, 2023. Realized loss
on short-term investment from wealth management financial products was $3,094,084 for the six months ended March 31, 2024, compared to
realized income on short-term investment of $166,931 for the six months ended March 31, 2023. The Company’s short-term investment
consists of non-rated company bonds and shares of public companies, which represented 93.1% and 6.9% of the total investment as of March
31, 2024, respectively. The number of global corporate defaults nearly doubled in 2023 as inflation and higher interest rates squeezed
some issuers’ cash flows. Furthermore, financing conditions were challenging for the lowest-rated borrowers and funding liquidity
was tight. The Company incurred approximately 90% loss for two disposed bonds, and recorded change in fair value of short-term investment
of $7,617,502 for its bond holdings during the six months ended March 31, 2024. No change in fair value of short-term investment was recognized
for the six months ended March 31, 2023.
Provision for Income Taxes
Provision for income taxes was $665,148 for the
six months ended March 31, 2024, representing a decrease of $309,210, or 31.7%, from $974,358 for the six months ended March 31, 2023,
due to decreased taxable income. As the Company’s PRC principal subsidiaries, Jiangxi Universe Pharmaceuticals Co., Ltd. and Jiangxi
Universe Pharmaceuticals Trade Co., Ltd., incurred net loss during the six months ended March 31, 2024, the Company evaluated the likelihood
of the realization of deferred tax assets, determined that deferred tax assets arising from net operating loss carry-forwards in previous
years might not be fully realized, and recognized $665,148 in valuation allowance for deferred tax assets during the six months ended
March 31, 2024.
Net Loss
Net loss was $13,101,457 for the six months ended
March 31, 2024, representing a $12,386,030 decrease from a net loss of $715,427 for the six months ended March 31, 2023.
Basic and diluted loss per share were $3.59 for
the six months ended March 31, 2024, compared with basic and diluted loss per share of $0.20 for the six months ended March 31, 2023.
Liquidity and Capital Resources
As of March 31, 2024, we had $8.9 million in cash
on hand. We also had short-term investments of $2.5 million in wealth management financial products from financial institutions to generate
investment income, which we purchased with our IPO proceeds. Such short-term investment can be redeemed anytime at our discretion and
is highly liquid. As of March 31, 2024, we also had $14.4 million in accounts receivable. Our accounts receivable primarily include balance
due from customers for our pharmaceutical products sold and delivered to customers. Approximately 81.0%, or $11.7 million, of our net
accounts receivable balance as of March 31, 2024 has been subsequently collected. Collected accounts receivable will be used as working
capital in our operations, if necessary.
As of March 31, 2024, our inventory balance
amounted to $3.4 million, primarily consisting of raw materials, work-in-progress and finished TCMD products, which we believe are able
to be sold quickly based on the analysis of the current trends in demand for our products.
On June 25, 2021, we signed a construction sub-contract
with sub-contractor Jiangxi Chenyuan Construction Project Co., Ltd. (“Chenyuan”), pursuant to which, Chenyuan will help us
construct four manufacturing plant buildings and an office building with a total estimated budget of RMB165 million (approximately $22.9
million). As of March 31, 2024, we had made a prepayment of approximately RMB69.2 million (approximately $9.6
million) to Chenyuan and future additional capital expenditure on this constriction-in-process (“CIP”) project was estimated
to be approximately RMB95.8 million (equivalent to $13.3 million), among which approximately
$3.4 million is required for the next 12 months. We currently plan to support our ongoing CIP project through cash collected from accounts
receivable, and if necessary, borrowings from banks.
On May 6, 2021, we entered into a real estate
property purchase agreement with a related party, Jiangxi Yueshang Investment Co., Ltd. (“Jiangxi Yueshang”), an entity in
which our chief executive officer, Mr. Gang Lai, owned 5% of its equity interests as of the date of that agreement. Pursuant to this purchase
agreement, Jiangxi Yueshang will sell and we will purchase certain residential apartments and commercial office space totaling 2,749.30
square meters, with a total purchase price of RMB32 million (approximately $4.4 million). As of March 31, 2024, we had made a prepayment
of RMB16 million (approximately $2.2 million) to Jiangxi Yueshang. The remaining balance is expected to be paid by April
2025.
As of March 31, 2024, we also had short-term bank
loans of $4.4 million and long-term bank loans of $2.1 million that we obtained from several PRC banks for working capital purposes. We
expect that we will be able to renew all of the existing bank loans upon their maturity based on our past experiences and our outstanding
credit history.
As of March 31, 2024, our working capital balance
was $13.0 million. In assessing our liquidity, management monitors and analyzes our cash on-hand, our ability to generate sufficient revenue
in the future, and our operating and capital expenditure commitments. We believe that our current cash and cash flows provided by operating
activities, borrowings from banks and from our principal shareholders will be sufficient to meet our working capital needs in the next
12 months from the date our unaudited condensed consolidated financial statements for the six months ended March 31, 2024 are released.
The following table sets forth summary of our
cash flows for the periods indicated:
| |
For the six Months Ended March 31, | |
| |
2024 | | |
2023 | |
Net cash (used in) provided by operating activities | |
$ | (2,429,621 | ) | |
$ | 4,798,702 | |
Net cash used in investing activities | |
| (67,656 | ) | |
| (646 | ) |
Net cash provided by financing activities | |
| 6,067,732 | | |
| 2,080,918 | |
Effect of exchange rate change on cash and restricted cash | |
| 5,888 | | |
| 364,084 | |
Net increase in cash | |
| 3,576,343 | | |
| 7,243,058 | |
Cash, beginning of period | |
| 5,285,247 | | |
| 5,711,458 | |
Cash, end of period | |
$ | 8,861,590 | | |
$ | 12,954,516 | |
Operating Activities
Net cash used in operating activities was $2,429,621
for the six months ended March 31, 2024, primarily consisted of the following:
|
● |
Net loss of $13,101,457 for the period. |
|
● |
Short-term investment impairment loss of $7,617,502 and short-term investment (loss) income of $3,094,084 due to deterioration of global corporate defaults. |
|
● |
An increase in accounts receivable of $3,346,205. We provided longer credit terms for our regular customers to maintain customer relationship and promote sales. As of date of this report, approximately 81.0%, or $11.7 million of our net accounts receivable balance as of March 31, 2024 has been subsequently collected. |
|
● |
An increase in accounts payable of $3,136,661 due to pending invoices from suppliers for raw materials purchased in the first quarter of 2024. |
|
● |
A decrease in deferred income tax benefit of $665,148 as we recognized valuation allowance for deferred tax assets during the six months ended March 31, 2024. |
Net cash provided by operating activities was
$4,798,702 for the six months ended March 31, 2023, primarily consisted of the following:
|
● |
Net loss of $715,427 for the period. |
|
● |
An increase in accounts payable of $7,928,308 due to pending invoices from suppliers for raw materials purchased in the first quarter of 2023. |
|
● |
An increase in accounts receivable of $1,763,903. Our accounts receivable primarily includes balance due from customers for our pharmaceutical products sold and delivered to customers. |
|
● |
A decrease in deferred income tax benefit of $556,867 as we utilized deferred tax asset in the six months ended March 31, 2024. |
|
● |
An increase in inventory balance of $488,746 because we increased inventory stockpiles to reduce the negative impact from increased market price of Chinese traditional medicine raw materials. |
|
● |
A decrease in accrued expenses and other current liabilities of $465,431 due to payments made to our advertising service provider in the six months ended March 31, 2023. |
Investing Activities
Net cash used in investing activities amounted
to $67,656 for the six months ended March 31, 2024, due to purchase of fixed assets of $30,189, prepayments for construction in progress
of $37,467, as well as purchase and sale of short-term investments of $313,541.
Net cash used in investing activities amounted
to $646 for the six months ended March 31, 2023, due to purchase of fixed assets.
Financing Activities
Net cash provided by financing activities amounted
to $6,067,732 for the six months ended March 31, 2024, primarily include the following:
|
● |
Proceeds from long-term bank loans of $2,081,483 and repayment of short-term bank loans of $1,110,124. |
|
● |
Proceeds from related party borrowings of $5,096,373. The balance due to related party mainly consisted of advances from Mr. Gang Lai for working capital purposes during our normal course of business. These advances were non-interest bearing and due on demand. |
Net cash provided by financing activities amounted
to $2,080,918 for the six months ended March 31, 2024, primarily include the following:
|
● |
Proceeds from short-term bank loans of $1,146,776 and repayment of bank loans of $1,146,776. |
|
● |
Proceeds from related party borrowings of $2,080,918. The balance due to related party mainly consisted of advances from Mr. Gang Lai for working capital purposes during our normal course of business. These advances were non-interest bearing and due on demand. |
Commitments and contingencies
From time to time, we are a party to various legal
actions arising in the ordinary course of business. We accrue costs associated with these matters when they become probable and the amount
can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred. For the six months ended
March 31, 2024 and 2023, we did not have any material legal claims or litigation that, individually or in aggregate, could have a material
adverse impact on our consolidated financial position, results of operations and cash flows.
As of March 31, 2024, we had the following contractual
obligations:
| |
Payments Due by Period | |
Contractual Obligations | |
Total | | |
Less than 1 year | | |
1-2 years | | |
2-3 years | |
(1) Debt Obligations | |
$ | 6,509,425 | | |
$ | 4,431,949 | | |
$ | 2,077,476 | | |
$ | - | |
(2) Capital expenditure commitment on CIP project | |
| 13,268,147 | | |
| 3,427,835 | | |
| 8,697,700 | | |
| 1,142,612 | |
(3) Capital expenditure commitment for purchase of property | |
| 2,215,974 | | |
| 2,215,974 | | |
| - | | |
| - | |
Total | |
$ | 21,993,546 | | |
$ | 10,075,759 | | |
$ | 10,775,176 | | |
$ | 1,142,612 | |
(1) |
As of March 31, 2024, we had total of $4,431,949 in short-term borrowings and $2,077,476 in long-term borrowings from several PRC banks (see Footnotes 12 and 13 of our unaudited consolidated financial statements and footnotes, for details). |
(2) |
On June 25, 2021, we signed a construction sub-contract with Chenyuan, pursuant to which, Chenyuan will help us construct four manufacturing plant buildings and an office building with a total estimated budget of RMB165 million (approximately $22.9 million). As of March 31, 2024, we had made a prepayment of approximately RMB69.2 million (approximately $9.6 million) to Chenyuan and future additional capital expenditure on this CIP project was estimated to be approximately RMB95.8 million (approximately $13.3 million) (see Footnote 10 of our unaudited consolidated financial statements and footnotes, Prepayment for CIP project, for details). |
(3) |
On May 6, 2021, we entered into a real estate property purchase agreement with a related party, Jiangxi Yueshang, an entity in which our chief executive officer, Mr. Gang Lai, owned 5% of its equity interests as of the date of that agreement. Pursuant to this purchase agreement, Jiangxi Yueshang will sell and we will purchase certain residential apartments and commercial office space totaling 2,749.30 square meters, with a total purchase price of RMB32 million (approximately $4.4 million). As of March 31, 2024, we had made a prepayment of RMB16 million (approximately $2.2 million) to Jiangxi Yueshang. The remaining balance is expected to be paid by April 2025 (see Footnote 11 of our unaudited consolidated financial statements and footnotes, Prepayment for purchase of a property, for details). |
Trend Information
Other than as disclosed elsewhere in this report,
we are not aware of any trends, uncertainties, demands, commitments, or events that are reasonably likely to have a material effect on
our net revenues, income from continuing operations, profitability, liquidity or capital resources, or that would cause reported financial
information not necessarily to be indicative of future operating results or financial condition.
Off-Balance Sheet Arrangements
We do not have any off-balance sheet arrangements
as of March 31, 2024 and September 30, 2023.
Inflation
Inflation does not materially affect our business
or the results of our operations.
Seasonality
Seasonality does not materially affect our business
or the results of our operations.
12
Exhibit 99.3
Universe Pharmaceuticals
INC Reports Financial Results for The First Six Months of Fiscal Year 2024
JI’AN, Jiangxi, China, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (the “Company,” “we,” “our” and “us”) (Nasdaq:
UPC), a pharmaceutical producer and distributor in China, today announced its unaudited financial results for the first six months of
fiscal year 2024 ended March 31, 2024.
Mr. Gang Lai, Chairman
of the Board of Directors and CEO of Universe Pharmaceuticals INC, commented, “During the first six months of fiscal year 2024,
we navigated business uncertainties and adjusted our business strategy to offset the impact of the global economic slowdown. As a result,
we generated $12.9 million in revenue for the six months ended March 31, 2024, lower than the $18.5 million revenue generated in the same
period of last year. We made considerable efforts to implement our growth strategies during this challenging period. To complement our
offline sales channels, we started developing online sales channels, which helped us seize more opportunities and we expect online sales
to drive our business growth in the fast-evolving market. Through executing our growth strategy of emphasizing digital marketing and expanding
our sales on e-commerce platforms, our goal is to improve our brand recognition, deliver products to more customers, and expand our business
scale. Looking forward, we intend to continue implementing our expansion strategy, through which we hope to achieve greater market penetration
and customer base expansion, with the goal of creating long-term value for our shareholders.”
Financial Highlights for the Six Months
Ended March 31, 2024
| |
For the Six Months Ended March 31, | |
($ millions, except per share data) | |
2024 | | |
2023 | | |
% Change | |
Revenues | |
| 12.9 | | |
| 18.5 | | |
| -30.2 | % |
(Loss) income from operations | |
| (1.7 | ) | |
| 0.1 | | |
| -1,266.0 | % |
Net loss | |
| (13.1 | ) | |
| (0.7 | ) | |
| 1,731.3 | % |
Loss per share | |
| (3.59 | ) | |
| (0.20 | ) | |
| 1,720.7 | % |
|
● |
Revenues decreased by 30.2% to $12.9 million for the six months ended March 31, 2024 from $18.5 million for the six months ended March 31, 2023, primarily attributable to decreased sales volume of the Company’s traditional Chinese medicine derivatives (“TCMD”) products and third-party products by 1,863,919 and 1,712,660 units, or 23.4% and 29.9%, respectively, due to decrease in customer demand resulted from economic slowdown, as well as a 3.3% negative impact from fluctuations in foreign currency exchange rate. |
|
● |
Loss from operations was $1.7 million for the six months ended March 31, 2024, compared to an income from operations of $0.1 million for the six months ended March 31, 2023, due to the decrease in revenue as discussed above. |
|
● |
Net loss was $13.1 million for the six months ended March 31, 2024, compared to a net loss of $0.7 million for the six months ended March 31, 2023. Realized loss on short-term investments from wealth management financial products was $3,094,084 for the six months ended March 31, 2024, compared to short-term investment income of $166,931 for the six months ended March 31, 2023. The Company also recorded change in fair value of short-term investment of $7,617,502 for its investment holdings during the six months ended March 31, 2024. No change in fair value of short-term investment was recognized for the six months ended March 31, 2023. |
|
● |
Loss per share was $3.59 for the six months ended March 31, 2024, compared to loss per share of $0.20 for the six months ended March 31, 2023. |
Financial Results for the Six Months Ended
March 31, 2024 Compared to the Six Months Ended March 31, 2023
Revenues
Total revenues decreased
by $5,582,816, or 30.2%, to $12,884,370 for the six months ended March 31, 2024, from $18,467,186 for the six months ended March 31, 2023.
| |
For the Six Months Ended March 31, | |
| |
2024 | | |
2023 | |
| |
Revenue | | |
Cost of
revenue | | |
Gross
margin | | |
Revenue | | |
Cost of
revenue | | |
Gross
margin | |
TCMD products sales | |
$ | 6,870,591 | | |
$ | 5,602,807 | | |
| 18.5 | % | |
$ | 9,374,312 | | |
$ | 6,617,444 | | |
| 29.4 | % |
Third-party products sales | |
| 6,013,779 | | |
| 3,912,232 | | |
| 34.9 | % | |
| 9,092,874 | | |
| 5,721,600 | | |
| 37.1 | % |
Total | |
$ | 12,884,370 | | |
$ | 9,515,039 | | |
| 26.2 | % | |
$ | 18,467,186 | | |
$ | 12,339,044 | | |
| 33.2 | % |
Sales of TCMD products
decreased by $2,503,721, or 26.7%, to $6,870,591 for the six months ended March 31, 2024, from $9,374,312 for the six months ended March
31, 2023. The decrease in the sales of TCMD products was mainly attributable to the following: (i) a 23.4% decrease in sales volume of
TCMD products by 1,863,919 units, to 6,097,325 units sold in the six months ended March 31, 2024, from 7,961,244 units sold in the six
months ended March 31, 2023. Global economic slowdown has led to a decline in customers’ spending power, and customer demand decreased
during the six months ended March 31, 2024; and (ii) a 3.3% negative impact from fluctuations in foreign currency exchange rate, as the
average exchange rate used in converting Renminbi (“RMB”) into U.S. dollars (“USD”) changed from US$1 to RMB6.9761
in for the six months ended March 31, 2023 to US$1 to RMB7.2064 in the six months ended March 31, 2024.
Sales of third-party products decreased by $3,079,095,
or 33.9%, to $6,013,779 for the six months ended March 31, 2024, from $9,092,874 for the six months ended March 31, 2023. The decrease
in the sales of third-party products was mainly attributable to the following: (i) a 29.9% decrease in sales volume of third-party products
by 1,712,660 units, to 4,014,841 units sold in the six months ended March 31, 2024, from 5,727,501 units sold in the six months ended
March 31, 2023 due to a decline in customer demand; and (ii) a 3.3% negative impact from fluctuations in foreign currency exchange rate.
Cost of revenues
and Gross profit
Cost of revenues decreased
by $2,824,005, or 22.9%, to $9,515,039 for the six months ended March 31, 2024, from $12,339,044 for the six months ended March 31, 2023,
due to a decrease in sales volume of the Company’s TCMD products and third-party products, partially offset by an increase in the
average cost of TCMD products by $0.09, or 10.8%, from $0.83 for the six months ended March 31, 2023 to $0.92 for the six months ended
March 31, 2024. In the summer of 2023, a severe flood in Anhui Province and Hubei Province of China, which are two main producing areas
of traditional Chinese medicinal materials, led to a decrease in the supply of such materials and an increase in the prices of the traditional
Chinese medicine raw materials during the six months ended March 31, 2024.
Gross profit decreased
by $2,758,811 to $3,369,331 for the six months ended March 31, 2024, from $6,128,142 for the six months ended March 31, 2023. Gross margin
decreased by 7.0% to 26.2% for the six months ended March 31, 2024, from 33.2% for the six months ended March 31, 2023.
Operating expenses
Selling expenses increased by $1,723,849, or 74.0%,
to $4,054,357 for the six months ended March 31, 2024, from $2,330,508 for the six months ended March 31, 2023, primarily attributable
to (i) an increase in advertising expenses by $1,432,932, from $1,340,368 in the six months ended March 31, 2023, to $2,773,300 in the
six months ended March 31, 2024. The Company entered into advertising service agreement with Health
Headline to promote its brand on the Health Headline’s website and mobile app. The Company increased publicity efforts for its products
and brand, and the advertising expenses increased significantly during the six months ended March 31, 2024; and (ii) an increase
in salary and employee benefit expenses by $112,104, or 32.1%, as the Company recruited 10 new employees in the marketing department to
promote sales of its products.
General and administrative
expenses decreased by $411,445, or 29.8%, to $968,608 for the six months ended March 31, 2024 from $1,380,053 for the six months ended
March 31, 2023, primarily attributable to (i) a decrease in bad debt expense by $265,530, because the Company accrued less bad debt expenses
based on its assessment of the collectability of the accounts receivable and advance to suppliers; and (ii) a decrease in office supply
and utility expense by $217,681 due to cost savings.
Research and development
expenses decreased by $2,181,832, or 96.2%, to $86,503 for the six months ended March 31, 2024, from $2,268,335 for the six months ended
March 31, 2023, primarily attributable to (i) a decrease in development expenditure on improving production process of the Company’s
Chinese medicine products in the amount of $1,505,144. The Company entered into several cooperative agreements with external academic
and research institutions to jointly conduct development of eight production process to improve production efficiency and product quality,
with activities beginning in August 2022, and incurred significant amount of research and development expense in connection with such
efforts during the six months ended March 31, 2023. These development activities were completed and results were integrated in production
in September 2023, and no such expenses incurred during the six months ended March 31, 2024; and (ii) a decrease in the materials used
in the research and development activities by $666,765 in connection with development activities on improving production process.
Other income (expenses),
net
Total other expenses,
net was $10,696,172 for the six months ended March 31, 2024, compared to total other income of $109,685 for the six months ended March
31, 2023. Realized loss on short-term investment from wealth management financial products was $3,094,084 for the six months ended March
31, 2024, compared to realized income on short-term investment of $166,931 for the six months ended March 31, 2023. The Company’s
short-term investment consists of non-rated company bonds and shares of public companies, which represented 93.1% and 6.9% of the total
investment as of March 31, 2024, respectively. The number of global corporate defaults nearly doubled in 2023 as inflation and higher
interest rates squeezed some issuers’ cash flows. Furthermore, financing conditions were challenging for the lowest-rated borrowers
and funding liquidity was tight. The Company incurred approximately 90% loss for two disposed bonds, and recorded change in fair value
of short-term investment of $7,617,502 for its bond holdings during the six months ended March 31, 2024. No change in fair value of short-term
investment was recognized for the six months ended March 31, 2023.
Provision for income
taxes
Provision for income
taxes was $665,148 for the six months ended March 31, 2024, representing a decrease of $309,210, or 31.7%, from $974,358 for the six months
ended March 31, 2023, due to decreased taxable income. As the Company’s PRC principal subsidiaries, Jiangxi Universe Pharmaceuticals
Co., Ltd. and Jiangxi Universe Pharmaceuticals Trade Co., Ltd., incurred net loss
during the six months ended March 31, 2024, the Company evaluated the likelihood of the realization of deferred tax assets, determined
that deferred tax assets arising from net operating loss carry-forwards in previous years might not be fully realized, and recognized
$665,148 in valuation allowance for deferred tax assets during the six months ended March 31, 2024.
Net loss
Net loss was $13,101,457
for the six months ended March 31, 2024, representing a $12,386,030 decrease from a net loss of $715,427 for the six months ended March
31, 2023.
Basic and diluted loss
per share were $3.59 for the six months ended March 31, 2024, compared with basic and diluted loss per share of $0.20 for the six
months ended March 31, 2023.
Balance Sheet
As of March 31, 2024,
the Company had cash of $8,861,590, as compared to $5,285,247 as of September 30, 2023.
Cash Flow
Net cash used in operating activities was $2,429,621
for the six months ended March 31, 2024, compared with cash provided by operating activities of $4,798,702 for the six months
ended March 31, 2023.
Net cash used in investing
activities was $67,656 for the six months ended March 31, 2024, compared with $646 for the six months ended March 31, 2023.
Net cash provided by
financing activities was $6,067,732 for the six months ended March 31, 2024, compared with $2,080,918 for the six months ended March
31, 2023.
Subsequent Event
On July 15, 2024, the
Company closed its self-underwritten public offering (“Offering”) of 20,000,000 ordinary shares, par value $0.01875 per share
(the “Ordinary Shares”). The Ordinary Shares were priced at $1.25 per share. The Company raised a total of $25 million through
that Offering, before deducting Offering-related expenses.
About Universe Pharmaceuticals INC
Universe Pharmaceuticals
INC, headquartered in Ji’an, Jiangxi, China, is a pharmaceutical producer and distributor in China. The Company specializes in the
manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives products targeting the elderly with the goal
of addressing their physical conditions in the aging process and to promote their general well-being. The Company also distributes and
sells biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces, and dietary supplements manufactured by third-party
pharmaceutical companies. Currently, the Company’s products are sold in 30 provinces of China. For more information, visit the company’s
website at http://www.universe-pharmacy.com/.
Forward-Looking
Statements
All statements other
than statements of historical fact in this announcement are forward-looking statements. These forward-looking statements involve known
and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that
the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify
these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,”
“aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,”
“is/are likely to” or other similar expressions. The Company undertakes no obligation to update forward-looking statements
to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the
Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations
will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results
and encourages investors to review other factors that may affect its future results in the Company’s most recent annual report on
Form 20-F and in its other filings with the U.S. Securities and Exchange Commission.
For more information, please contact:
Email:IR@universe-pharmacy.com
Phone:+86-0796-8403687
UNIVERSE PHARMACEUTICALS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
| |
As of | |
| |
March
31,
2024 | | |
September 30,
2023 | |
| |
(Unaudited) | | |
| |
ASSETS | |
| | |
| |
CURRENT ASSETS | |
| | |
| |
Cash | |
$ | 8,861,590 | | |
$ | 5,285,247 | |
Short-term investments | |
| 2,527,603 | | |
| 13,219,005 | |
Accounts receivable, net | |
| 14,384,228 | | |
| 10,667,603 | |
Due from related parties | |
| - | | |
| 61,678 | |
Inventories, net | |
| 3,386,052 | | |
| 3,343,266 | |
Advance to suppliers | |
| 368,960 | | |
| 180,643 | |
Prepayment for acquisition | |
| 3,462,460 | | |
| 3,426,535 | |
Prepaid expenses and other current assets | |
| 539,240 | | |
| 590,377 | |
TOTAL CURRENT ASSETS | |
| 33,530,133 | | |
| 36,774,354 | |
| |
| | | |
| | |
Property, plant and equipment, net | |
| 3,522,997 | | |
| 3,699,965 | |
Prepayments made to a related party for purchase of property | |
| 2,215,974 | | |
| 2,192,982 | |
Prepayments for construction in progress | |
| 9,225,725 | | |
| 9,092,996 | |
Intangible assets, net | |
| 147,652 | | |
| 148,584 | |
Investment in equity securities | |
| 692,492 | | |
| 685,307 | |
Deferred tax assets | |
| - | | |
| 656,980 | |
Prepaid expenses-related party, non-current | |
| 96,141 | | |
| 35,864 | |
TOTAL NONCURRENT ASSETS | |
| 15,900,981 | | |
| 16,512,678 | |
| |
| | | |
| | |
TOTAL ASSETS | |
$ | 49,431,114 | | |
$ | 53,287,032 | |
| |
| | | |
| | |
LIABILITIES AND SHAREHOLDERS’ EQUITY | |
| | | |
| | |
| |
| | | |
| | |
CURRENT LIABILITIES | |
| | | |
| | |
Short-term bank loans | |
$ | 4,431,949 | | |
$ | 5,482,456 | |
Accounts payable | |
| 7,763,981 | | |
| 4,585,285 | |
Taxes payable | |
| 172,374 | | |
| 434,758 | |
Due to related parties | |
| 5,515,160 | | |
| 540,096 | |
Accrued expenses and other current liabilities | |
| 2,726,078 | | |
| 2,711,736 | |
TOTAL CURRENT LIABILITIES | |
| 20,609,542 | | |
| 13,754,331 | |
| |
| | | |
| | |
Long-term bank loans | |
| 2,077,476 | | |
| - | |
TOTAL LIABILITIES | |
| 22,687,018 | | |
| 13,754,331 | |
| |
| | | |
| | |
COMMITMENTS AND CONTINGENCIES | |
| | | |
| | |
| |
| | | |
| | |
SHAREHOLDERS’ EQUITY | |
| | | |
| | |
Ordinary shares, $0.01875 par value, 166,666,666 shares authorized, 3,645,974 and 3,625,000 shares issued and outstanding as of March 31, 2024 and September 30, 2023, respectively | |
| 68,362 | | |
| 67,969 | |
Additional paid in capital | |
| 29,278,766 | | |
| 29,279,159 | |
Statutory reserve | |
| 2,439,535 | | |
| 2,439,535 | |
Retained earnings | |
| (2,942,153 | ) | |
| 10,159,304 | |
Accumulated other comprehensive loss | |
| (2,100,414 | ) | |
| (2,413,266 | ) |
TOTAL SHAREHOLDERS’ EQUITY | |
| 26,744,096 | | |
| 39,532,701 | |
| |
| | | |
| | |
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | |
$ | 49,431,114 | | |
$ | 53,287,032 | |
UNIVERSE PHARMACEUTICALS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
AND COMPREHENSIVE INCOME
(UNAUDITED)
| |
For the Six Months Ended March 31, | |
| |
2024 | | |
2023 | |
| |
| | |
| |
REVENUE | |
$ | 12,884,370 | | |
$ | 18,467,186 | |
COST OF REVENUE AND RELATED TAX | |
| 9,515,039 | | |
| 12,339,044 | |
GROSS PROFIT | |
| 3,369,331 | | |
| 6,128,142 | |
| |
| | | |
| | |
OPERATING EXPENSES | |
| | | |
| | |
Selling expenses | |
| 4,054,357 | | |
| 2,330,508 | |
General and administrative expenses | |
| 968,608 | | |
| 1,380,053 | |
Research and development expenses | |
| 86,503 | | |
| 2,268,335 | |
Total operating expenses | |
| 5,109,468 | | |
| 5,978,896 | |
| |
| | | |
| | |
INCOME (LOSS) FROM OPERATIONS | |
| (1,740,137 | ) | |
| 149,246 | |
| |
| | | |
| | |
OTHER INCOME (EXPENSES) | |
| | | |
| | |
Interest expense, net | |
| (136,613 | ) | |
| (74,569 | ) |
Other income, net | |
| 152,027 | | |
| 17,323 | |
Realized (loss) gain on short-term investments | |
| (3,094,084 | ) | |
| 166,931 | |
Change in fair value of short-term investments | |
| (7,617,502 | ) | |
| - | |
Total other (loss) income, net | |
| (10,696,172 | ) | |
| 109,685 | |
| |
| | | |
| | |
(LOSS) INCOME BEFORE INCOME TAX PROVISION | |
| (12,436,309 | ) | |
| 258,931 | |
| |
| | | |
| | |
PROVISION FOR INCOME TAXES | |
| 665,148 | | |
| 974,358 | |
| |
| | | |
| | |
NET LOSS | |
| (13,101,457 | ) | |
| (715,427 | ) |
| |
| | | |
| | |
OTHER COMPREHENSIVE INCOME | |
| | | |
| | |
Foreign currency translation adjustment | |
| 312,852 | | |
| 1,399,775 | |
COMPREHENSIVE (LOSS) INCOME | |
$ | (12,788,605 | ) | |
$ | 684,348 | |
| |
| | | |
| | |
Earnings per ordinary share - basic and diluted | |
$ | (3.59 | ) | |
$ | (0.20 | ) |
Weighted average shares - basic and diluted | |
$ | 3,645,974 | | |
$ | 3,625,000 | |
CONDENSED CONSOLIDATED STATEMENTS
OF CHANGES IN SHAREHOLDERS’ EQUITY
FOR THE SIX MONTHS
ENDED MARCH 31, 2024 AND 2023
(UNAUDITED)
| |
| | |
| | |
| | |
| | |
Accumulated | | |
| |
| |
| | |
Additional | | |
| | |
| | |
Other | | |
| |
| |
Ordinary Share | | |
Paid in | | |
Statutory | | |
Retained | | |
Comprehensive | | |
| |
| |
Shares | | |
Amount | | |
Capital | | |
Reserve | | |
Earnings | | |
Income | | |
Total | |
Balance at September 30, 2022 | |
| 3,625,000 | | |
$ | 67,969 | | |
$ | 29,279,159 | | |
$ | 2,439,535 | | |
$ | 16,322,365 | | |
$ | (1,666,705 | ) | |
$ | 46,442,323 | |
Net loss | |
| - | | |
| - | | |
| - | | |
| - | | |
| (715,427 | ) | |
| - | | |
| (715,427 | ) |
Foreign currency translation adjustment | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 1,399,775 | | |
| 1,399,775 | |
Balance at March 31, 2023 | |
| 3,625,000 | | |
$ | 67,969 | | |
$ | 29,279,159 | | |
$ | 2,439,535 | | |
$ | 15,606,938 | | |
$ | (266,930 | ) | |
$ | 47,126,671 | |
| |
| | |
| | |
| | |
| | |
| | |
| |
| |
| | |
| | |
| | |
| | |
Accumulated | | |
| |
| |
| | |
Additional | | |
| | |
| | |
Other | | |
| |
| |
Ordinary Share | | |
Paid in | | |
Statutory | | |
Retained | | |
Comprehensive | | |
| |
| |
Shares | | |
Amount | | |
Capital | | |
Reserve | | |
Earnings | | |
Income | | |
Total | |
Balance at September 30, 2023 | |
| 3,625,000 | | |
$ | 67,969 | | |
$ | 29,279,159 | | |
$ | 2,439,535 | | |
$ | 10,159,304 | | |
$ | (2,413,266 | ) | |
$ | 39,532,701 | |
Reverse share-split adjustment | |
| 20,974 | | |
| 393 | | |
| (393 | ) | |
| - | | |
| - | | |
| - | | |
| - | |
Net loss | |
| - | | |
| - | | |
| - | | |
| - | | |
| (13,101,457 | ) | |
| - | | |
| (13,101,457 | ) |
Foreign currency translation adjustment | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 312,852 | | |
| 312,852 | |
Balance at March 31, 2024 | |
| 3,645,974 | | |
$ | 68,362 | | |
$ | 29,278,766 | | |
$ | 2,439,535 | | |
$ | (2,942,153 | ) | |
$ | (2,100,414 | ) | |
$ | 26,744,096 | |
UNIVERSE PHARMACEUTICALS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS
OF CASH FLOWS
(UNAUDITED)
|
|
For the Six Months Ended
March 31, |
|
|
|
2024 |
|
|
2023 |
|
Cash flows from operating activities: |
|
|
|
|
|
|
Net loss |
|
$ |
(13,101,457 |
) |
|
$ |
(715,427 |
) |
Adjustments to reconcile net income to net cash provided by operating activities: |
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
|
248,860 |
|
|
|
257,781 |
|
Gain from disposal of fixed assets |
|
|
- |
|
|
|
(115 |
) |
Changes in allowance for doubtful accounts |
|
|
(265,530 |
) |
|
|
- |
|
Changes in inventory reserve |
|
|
(34,303 |
) |
|
|
(84,956 |
) |
Deferred income tax provision |
|
|
665,148 |
|
|
|
556,867 |
|
Realized loss (gain) on short-term investments |
|
|
3,094,084 |
|
|
|
(166,931 |
) |
Change in fair value of short-term investments |
|
|
7,617,502 |
|
|
|
- |
|
Changes in operating assets and liabilities: |
|
|
|
|
|
|
|
|
Accounts receivable |
|
|
(3,346,205 |
) |
|
|
(1,763,903 |
) |
Inventories |
|
|
26,553 |
|
|
|
(488,746 |
) |
Advance to suppliers, net |
|
|
(186,782 |
) |
|
|
(187,460 |
) |
Prepaid expenses and other current assets |
|
|
57,436 |
|
|
|
(220,969 |
) |
Prepaid expenses-related party, non-current |
|
|
(60,016 |
) |
|
|
- |
|
Accounts payable |
|
|
3,136,661 |
|
|
|
7,928,308 |
|
Taxes payable |
|
|
(267,456 |
) |
|
|
149,684 |
|
Accrued expenses and other current liabilities |
|
|
(14,116 |
) |
|
|
(465,431 |
) |
Net cash (used in) provided by operating activities |
|
|
(2,429,621 |
) |
|
|
4,798,702 |
|
|
|
|
|
|
|
|
|
|
Cash flows from investing activities: |
|
|
|
|
|
|
|
|
Purchases of property and equipment |
|
|
(30,189 |
) |
|
|
(646 |
) |
Prepayments for construction in progress |
|
|
(37,467 |
) |
|
|
- |
|
Purchase of short-term investments |
|
|
(313,541 |
) |
|
|
- |
|
Sale of short-term investments |
|
|
313,541 |
|
|
|
- |
|
Net cash used in investing activities |
|
|
(67,656 |
) |
|
|
(646 |
) |
|
|
|
|
|
|
|
|
|
Cash flows from financing activities: |
|
|
|
|
|
|
|
|
Proceeds from bank loans |
|
|
2,081,483 |
|
|
|
1,146,776 |
|
Repayment of bank loans |
|
|
(1,110,124 |
) |
|
|
(1,146,776 |
) |
Proceeds from related party borrowings |
|
|
5,096,373 |
|
|
|
2,080,918 |
|
Net cash provided by financing activities |
|
|
6,067,732 |
|
|
|
2,080,918 |
|
|
|
|
|
|
|
|
|
|
Effect of changes of foreign exchange rates on cash |
|
|
5,888 |
|
|
|
364,084 |
|
Net increase in cash |
|
|
3,576,343 |
|
|
|
7,243,058 |
|
Cash, beginning of period |
|
|
5,285,247 |
|
|
|
5,711,458 |
|
Cash, end of period |
|
$ |
8,861,590 |
|
|
$ |
12,954,516 |
|
|
|
|
|
|
|
|
|
|
Supplemental disclosure of cash flow information |
|
|
|
|
|
|
|
|
Cash paid for interest |
|
$ |
148,860 |
|
|
$ |
90,044 |
|
Cash paid for income tax |
|
$ |
969,914 |
|
|
$ |
575,132 |
|
v3.24.3
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|